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1INTRODUCTION
Pain is basically an unpleasant sensory and emotional feel mostly related
with definite or potential tissue damage or sometimes also described in terms
of such damage. It is an unpleasant subjective sensation which can only be
experienced and not expressed in any terms. The basic purpose to treat or
prevent pain is humanitarian. Acute pain is mostly linked with a short-lived
episode of tissue damage or inflammation which may be caused for example
by trauma or surgery. Commonly the intensity of the pain decreases gradually
over a period of time as there is reduction in causative factor like injury or
inflammation. One another important cause of pain id post-operative pain. The
regional anaesthetic techniques considerably reduces post-operative pain and
systemic analgesic requirements. Effective pain control is a must for ideal care
of surgical patients. Sufficient post-operative pain relief must be a fundamental
part of administration of anaesthesia. Insufficient post-operative pain relief
may end up in clinical and psychological changes that may escalate the
morbidity and mortality as well as the financial burden as a whole also affecting
the quality of life post –operatively.
The usage of epidural analgesia for the managing post-operative pain has
developed as a important component of multi modal methodology to reach the
role of adequate analgesia with an improved outcome. Epidural analgesia also
gives us a much superior post-operative pain relief in comparison with systemic
2drugs. Along with improved pain control, epidural analgesia also improves
patient outcome by decreasing unfavourable post-operative stress.(20,21)
Sedation, stable hemodynamics and the capacity to provide smooth and
extended period of post-operative analgesia are the important assets of an
adjuvant in post-operative epidural analgesia .α-2 adrenergic agonists like
clonidine have both analgesic and sedative properties when used as an adjuvant
in regional anaesthesia (2-6). Dexmedetomidine is one another drug which is a
highly selective α-2 adrenergic agonist with an affinity of eight times greater
than clonidine. The analgesic requirement gets decreased to a greater extent by
the using these adjuvants because of their analgesic properties and
intensification of local anaesthetic effects as they cause hyperpolarisation of
nerve tissues by altering transmembrane potential and ion conductance at locus
coeruleus in the brain stem. (11, 17, 18, 23, 24) The stable hemodynamic and
the reduced oxygen demand due to enhanced sympatho-adrenal stability make
them very handy pharmacologic agents.(36)
Keeping their pharmacologic actions and other properties we planned to
conduct a prospective randomized double blinded interventional study at our
institution in patients who underwent surgery for inguinal hernia under regional
anaesthesia with an aim to compare the analgesic and sedative effect of these
drugs given via epidural route as an adjuvant to ropivacaine in the post-
operative period.
3AIMS AND OBJECTIVES
PRIMARY OBJECTIVE:
To evaluate and compare the onset and duration of analgesia after adding
dexmeditomedine and clonidine with ropivacaine in epidural space for Inguinal
Hernia Surgeries.
SECONDARY OBJECTIVE:
To compare the sedative effects of dexmeditomedine and clonidine
without giving any other sedative drugs during intra and post-operative period.
4REVIEW OF LITERATURE
ANATOMY OF EPIDURAL SPACE
Epidural space or extradural space is a potential space located between
the duramater and the periosteum lining the vertebral canal and extends from
foramen magnum to sacral hiatus.
Spinal epidural space is bounded superiorly by fusion of spinal and
periosteal layer of duramater, below by sacrococcygeal ligament. Anteriorly
bounded by posterior longitudinal ligament, vertebral body and disc,
posteriorly by ligamentum flavum and capsule of facet joint while pedicles and
intervertebral foraminae forms lateral boundaries.
`Spinal epidural space can be categorized into cervical, thoracic, lumbar and
sacral spaces. It is roomier at upper thoracic level and measures 0.4mm at C7-
T1 level, 7.5mm at upper thoracic region, 4.1mm at T12-L1 level and 4-7mm
in lumbar region. Para vertebral spaces are communicates with each other in
the epidural space.
Epidural space is said to be under negative pressure except sacral region.
This epidural pressure is more negative in sitting posture than lateral decubitus
especially in thoracic levels. A basal value ranging from -1 to -7Cm H2O has
been observed
5Contents of epidural space:
The contents of epidural space includes Fat, Lymphatics, loose areolar
connective tissue, spinal nerve roots, and plexus of epidural veins. Epidural
arteries located in the lumbar regions are branches of iliolumbar arteries. Fat
cells are abundant in dura that forms sleeve around spinal nerve roots. The fat
in the epidural space buffers the pulsatile movement of the dural sac and protect
the nerve structure
Identification of epidural space:
Most of the traditional methods identifying the epidural space depends
upon the negative pressure exhibited during introduction of epidural needle in
the space. One of the most reliable method is Loss of Resistance (LOR) method
which uses air or liquid. other methods of identification includes modified drip
method, membrane in syringe method, use of Macintosh epidural balloon,
Epidrum and Episure syringe are also described in identifying epidural space.
6Clinical importance of epidural space:
Epidural space has been subjected to many clinical manipulation for the
purpose of anaesthesia and analgesia. Local anaesthetics with or without
opioid, steroids can be given by single shot or continuous or intermittent
manner using epidural catheters which produce clinical effects.
Physiological effects of epidural blockade
The primary site of action of local anaesthetic agents injected into the
epidural space is the spinal nerve roots. The segmental nerve roots in the
thoracic and lumbar regions are mixed nerves, which contains somatic,
sensory, motor, and autonomic nerve fibres. Sensory blockade interferes with
the communication of both somatic and visceral painful stimuli, whereas motor
blockade offers muscle relaxation with a different range of sympathetic
blockade. The injection site for epidural anaesthesia should be close to the
nerve roots on which its effect is required in order to obtain the best outcome
with minimal amount of local anaesthetic and lesser risk of side effects from
systemic absorption of the local anaesthetic. Differential nerve block, is one
another concept for epidural anaesthesia in which nerve fibres with diverse
functions exhibit a varying sensitivity to the effects of local anaesthetics.
Sympathetic fibres are generally blocked first followed by pain/temperature,
then proprioception, followed by motor blockade. After an epidural block,
sympathetic blockade (temperature) may vary from zero to four segments
7higher than the sensory block level (pain/light touch), which is two segments
higher than motor blockade. Whereas regression of the block occurs in reverse
order.
The physiologic effects of epidural blockade on organ systems depends
on the spinal level and the number of spinal segments blocked. In general, high
thoracic epidural blocks and extensive epidural blocks are concomitant with
more intense sympathetic block, resulting in a more profound physiologic
effect in the cardiovascular system.
Basically to be efficacious with epidural blockade, the clinician must
know the physiology of nerve conduction and the pharmacological action of
the local anaesthetics. Sufficient knowledge about potency and duration of
action of the drugs, their capacity to selectively block sensory and motor fibres
and also the in-depth prior knowledge about the expected duration of surgery
or need for postoperative analgesia are important factors to be considered
before injecting epidural blockade. The principal site of action of local
anaesthetics after epidural injection is thought to be the spinal nerve roots, the
spinal cord, and possibly the brain. Nerve fibres with different structures and
function display a wide range of sensitivity to local anaesthetic blockade. For
example, sympathetic fibres tend to be blocked with the lowest concentration
of drug, followed by pain, touch, and finally motor fibres.
8Classification of sensory fibers
Sensory fibres Speed oftransmission Sensory function Myelination
C fibres 0.5 -2m/sec Pain,cold , heat,touch. Unmyelinated
A-Alpha
fibres 70 -120m/sec
Noxious chemical
thermal, mechanical
stimuli . Myelinated
A-Beta fibres 30 -70m/sec
Light touch,
pressures,vibration
proprioception Myelinated
A-Gamma
fibres 30-70m/sec
Proprioception,
Motor to muscle
spindle
Myelinated
A-Delta fibres 12 -30 m/sec Pain, cold, touch Myelinated
B fibres 3 -15 m/sec
Pre ganglionic
autonomic
(sympathetic)
Myelinated
PAIN PATHWAYS
Pain receptors contain peripheral plexus of unmyelinated nerves,
stimulated by high-intensity provocation which may be thermal, mechanical,
electrical or chemical. Pain is conducted along two types of fibres in the
periphery, A delta fibres are finely myelinated and quite swiftly conducting
(12-30 m/sec). They mainly conduct the sharp pain produced by pin prick or
electrical stimulation as well as thermal stimuli and also importantly
responsible for withdrawal reflex. Pain conducted by A delta fibres is sensed
quickly and is well localised. ‘C’ fibres are very fine non-myelinated fibres
9which conduct at a very slow rate 2-3m/sec or less. Their threshold for
stimulation is higher and is responsible for delayed and truly noxious burning
or throbbing pain.
The activation of two different type of fibres (A delta &C) by noxious
stimuli explains the double sensation for pain evoked in the human by a single
short noxious stimulus, rapid pricking pain(0.1sec, latency, fast pain) carried
by A delta fibres is followed approximately one second later by a burning pain
(slow pain) mediated by C fibres.
PHYSIOLOGICAL CHANGES
While activity in sensory neurons may be excited in the periphery by
thermoreceptor, nociceptor or mechanoreceptor stimulation cell bodies in the
posterior horn are responsive to different intensities of stimulation. Thus
certain cells found principally in lamina IV respond only to a low intensity of
stimulation such as light touch. These are termed low threshold or LT cells.
They respond maximally to low- threshold stimuli and do not increase their
firing rate with increased stimulus intensity. They are therefore incapable of
conducting pain. Another type of cell, found principally in lamina V responds
over a wide range stimulus intensities, the so called wide-dynamic range or
WDR cells. Noxious stimuli can excite a variable response in WDR cells in
lamina V, a third type of cell is responsive to stimuli only within the noxious
range. Such cells are known as High threshold cells or HT cells and are found
mainly in lamina I. A delta and C fibre stimulation in the periphery results in
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increased firing in HT and WDR cells in lamina I and V which is conducted up
in spinothalamic tract. Surgery produces local tissue damage with consequent
release of algesic substances like prostaglandins, histamine, serotonin,
bradykinin, hydroxytryptamine, substance P and generation of noxious stimuli
that are transduced by nociceptors and transmitted by A delta and C fibres to
the neuraxis.
Segmental reflex responses associated with surgery includes
increased skeletal muscle tone and spasm with associated increase in O2
consumption and lactic acid production. Stimulation of sympathetic neuron
causes tachycardia, increased stroke volume, cardiac work and myocardial
oxygen consumption. Supra-segmental reflex responses result in further
increase in sympathetic tone and hypothalamic stimulation, metabolism and
increased O2 consumption. Hence the most obvious motive for relieving
postoperative pain is not only humanitarian but also to contribute a more rapid
and complete postoperative recovery.
Mechanism of action of local anaesthetics:
Local anaesthetic binds to sodium channels, primarily in the inactivated
state, preventing further activation of channel. Hence movement of sodium ion
into cell is prevented, therefore efficiently blocking the development of the
action potential. The resulting resting membrane potential is unaffected by
further nerve stimulation, referred to as membrane stabilization of local
anaesthetics.
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Mechanism of action of local anaesthetics in neural blockade:
Within the dorsal horn, local anaesthetics can block both sodium and
potassium ion channels in the dorsal horn neurons, inhibiting the production
and transmission of pain signals. Motor blockade occurs due to a similar action
on the ventral horn neurons. Inhibition of calcium ion channels in the spinal
cord leads to resistance of electrical stimulation from nociceptive afferent
nerves, generating an intense analgesic action seen in centrally administered
local anaesthetics.
Along with ion channel changes in the central neuraxis, epidurally
administered local anaesthetics indirectly impede the release of substance P
and other neurotransmitters which are involved in pain signal processing.
Substance P is one of neurotransmitter which is involved in pain transmission
from the presynaptic terminals of dorsal root ganglionic cells. The assumed
effect of centrally administered local anaesthetics on substance P and these
other transmitters is linked to the presynaptic blockade of the voltage-gated
12
calcium channel. When calcium entry is inhibited at the presynaptic level,
release of these neurotransmitters (glutamate, substance P, calcitonin gene-
related peptide [CGRP], neurokinin-1 and -2 [NK1, NK2]) at the presynaptic
level does not occur. Therefore, epidurally administered local anaesthetics can
indirectly inhibit pain signal conduction also.
Indications:
Injecting medication into the epidural space is principally done for analgesia.
Epidural analgesia may be used:
1. For analgesia alone, where surgery is not contemplated. An epidural
for pain reduction for example during childbirth.
2. As an adjunct to general anaesthesia.
The anaesthetist may use epidural analgesia as an adjuvant to general
anaesthesia. This may decrease the need of opioid analgesics. This is suitable
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for a wide variety of surgeries, for example gynaecological surgery (e.g.
hysterectomy), orthopaedic surgery (e.g. hip replacement), general surgery
(e.g. laparotomy) and vascular surgery (e.g. open aortic aneurysm repair).
3. As a sole technique for surgical anaesthesia.
In few situations most commonly Caesarean section may be executed
using an epidural anaesthetic as the sole technique. Characteristically the
patient would remain awake during the operation. The dose required for
anaesthesia in such conditions will be much higher than that required for
analgesia.
4. For post-operative analgesia
Particularly after a surgery where the epidural was used as either the sole
anaesthetic, or was used as an adjuvant with general anaesthesia. Analgesics
are given into the epidural space for a few days after surgery, provided a
catheter has been inserted.
Through the use of a patient controlled epidural analgesia (PCEA)
infusion pump, a patient has the ability to give an occasional extra dose of post-
surgical pain medications administered through the epidural route. This is most
commonly used in major surgeries.
Rarely epidural analgesia is used in conditions listed below,
For the treatment of back pain. Injection of analgesics and steroids into
the epidural space may improve some forms of back pain.
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For the treatment of chronic pain or palliation of symptoms in
terminal
Care of diseases like cancer.
POST OPERATIVE EPIDURAL ANALGESIA
The pain experienced after a surgery comprising the abdominal
musculature ends up in decrease of vital capacity of 70-75% in upper
abdominal and 50% in lower abdominal surgeries. Thoracic epidural analgesia
provides not only complete absence of pain, but also a very considerable
improvement in the vital capacity. Search for an ideal adjuvant for post-
operative epidural analgesia still continues that could result in reliable
prolongation of post-operative pain relief without side effects.
BENEFITS OF POST OPERATIVE EPIDURAL ANALGESIA
Cerebral: Improved post-OP cognition, reduction in CVA
Cardiovascular: Reduced MI, reduced blood loss, reduced transfusion
requirement, reduced DVT
Pulmonary: Reduced pulmonary infection, reduced pulmonary embolism,
reduced respiratory depression, reduced hypoxemia
Stress Response: reduced stress catecholamines
Gastrointestinal: Reduced post-operative paralytic ileus
Renal: Reduced ARF
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Surgical outcomes: Reduced length of stay in hospital, reduced morbidity &
mortality
Complications of epidural analgesia:
1. Subdural puncture
The patient should be assessed for a sudden or progressive increase in
adverse effects such as sedation, sensory and motor function loss, low BP.
2. Epidural abscess
The catheter insertion site should be evaluated every 8 hrs for any local
signs of infection i.e. tenderness, erythema, swelling, drainage. And also to
look for any changes in sensory/motor function every four hours including
unexplained back pain, bowel or bladder dysfunction, fever or neck stiffness.
3. Epidural haematoma
The catheter insertion site must be evaluated every 8 hours for pain and
or swelling at the site and also for changes in sensory/motor function for every
4 hrs including progressive numbness, weakness or bowel and bladder
dysfunction.
4. Migration of catheter into epidural vessels
The catheter may migrate into the blood vessels of the epidural space
causing the medications to be delivered systemically causing various effects.
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PHARMACOLOGY OF ROPIVACAINE
Ropivacaine is an amino amide local anaesthetic. It is a derivative of
pipecoloxylidide. Pipecoloxylidide are chiral drugs due to presence of
asymmetric carbon atoms and form two groups of S and R enantiomers.
Ropivacaine is a pure S enantiomer with chiral purity of 99.5%. Ropivacaine is
prepared by alkylation of S enantiomer of dibenzoy-l-tartaric acid
PHYSIOCHEMICAL PROPERTIES:
Chemical name as S-1-propyl-2,6- pipecoloxylidide hydrochloride
monohydrate.
Molecular weight of ropivacaine is 274KDa, pka is 8.07, pH is 7.4, they
has 94 % plasma protein binding capacity, and its lipid solubility partition co
efficient is 8.87. Plasma half-life is 111 minutes, Clearance is 10.3 L/minutes.
MECHANISM OF ACTION:
Ropivacaine acts through inhibition of sodium channel. It inhibits the
transmission of sodium ions through the channel and also potassium channel.
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Thus it stops the production and transmission of impulses along the nerve
fibres. It is irreversible type of blockade.
PHARMACOKINETIC PROPERTIES:
Absorption
The plasma concentration of ropivacaine is reliant on multiple elements
like route of administration, dose of drug administered, concentration of drug
used, blood supply of the region and hemodynamic status of patient. The mean
half-life is 14 minutes in first phase and 4 hours in second phase as it has
biphasic elimination. The rate limiting factor for ropivacaine is the slow
absorption from the epidural space. Hence ropivacaine has extended duration
of action through the epidural route.
Distribution
The protein bound fraction is about 94%. It mainly binds to α1- acid
glycoprotein. There is a surge in bound form of drug in post-operative period
as a result of increase in α-1-acid glycoprotein from stress response in surgery.
This is particularly so after continuous epidural infusion.
Metabolism
Ropivacaine is comprehensively metabolized in the liver. It is primarily
metabolised by aromatic hydroxylation which involves cytochrome P4501A to
3-hydroxy ropivacaine. About 37% of the total dose is excreted via urine. It is
excreted in both as free and conjugated form of 3-hydroxy ropivacaine. 3-OH-
ropivacaine and N-de-alkylated metabolite of ropivacaine are the major
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metabolites excreted in the urine. These are particularly produced during the
continuous epidural infusion.
Elimination
Ropivacaine is principally eliminated through the kidney as various
metabolites. About 86% of the total drug is excreted through the kidneys. The
total clearance is about 387 ml/min. The mean half-life is around 1.8 hrs after
iv route and about 4.2 hrs after epidural route.
PHARMACODYNAMIC PROPERTIES:
The type of blockade formed by ropivacaine hinge upon the
concentration of drug injected. In low concentration it blocks both Aδ and C
fibres which is more potent than that of equal concentration of bupivacaine. In
high concentration, the blockade of Aδ fibres’ is less than that of bupivacaine
while the blockade of C fibres is similar. The penetration of ropivacaine into
myelin sheath is less due to low lipid solubility compared to bupivacaine. Thus
it preferentially blocks C fibres than Aδ fibres. In toxic doses, it causes initial
excitation of nervous system expressing as restlessness, tremor, and
convulsions. Later it leads to depression of medullary centre and finally ends
up in coma.
Effect on Cardiovascular system
They are mainly due to blockade of sympathetic fibers. Hence there is
reduced venous return and reduced heart rate which causes hypotension.
Effect on respiratory system
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Normal doses doesn’t has any effect whereas higher doses leads to
toxicity producing respiratory depression along with medullary depressant
effect.
Ropivacaine is used in surgical anaesthesia, as spinal, epidural, caudal,
peripheral nerve block and infiltration anaesthesia. It is also used in pain
management in situations like labour analgesia where it is used as intermittent
bolus or continuous infusion.
Ropivacaine is contraindicated in patients who are allergic to amide type
of local anaesthetics. It also should be avoided in Intravenous regional
anaesthesia (Bier’s block), Obstetric Para cervical anaesthesia, patients with
hemodynamic instability, septicaemia, Local site infection.
The adverse reactions to ropivacaine are related to excessive plasma
levels due to over dosage, accidental intravascular injection or slow metabolic
degradation. The mean doses of plasma level at which adverse effects appear
are  about  4.3 and 0.6 μg/ ml of total and free plasma concentrations
respectively.
Common adverse effects:
Cardiovascular System – bradycardia, hypotension, vasovagal reaction,
syncope, arrhythmias.
Central and peripheral nervous System – dyskinesia, hypokinesia, neuropathy,
vertigo, tremors, paresis, neuropathy and coma.
Gastrointestinal System - nausea and vomiting, incontinence, tenesmus.
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Hearing and Vestibular - tinnitus, hearing abnormalities.
Hepato - Biliary System – jaundice
Musculoskeletal System – myalgia.
Psychiatric Disorders - agitation, confusion, nervousness, amnesia,
hallucination, emotional liability, insomnia, nightmares.
Skin Disorders - rash, urticaria.
Urinary System Disorders- urinary incontinence, micturition disorder.
Vascular - deep vein thrombosis, phlebitis, pulmonary embolism.
Ropivacaine is obtained in ampoules of isobaric solution in
concentration of 0.2%, 0.5%, 0.75% and 1%.
DOSAGES
Caudal - 1ml/kg of 0.2% solution.
Epidural - 15 to 20 ml of 0.2% or 0.5% solution.
Spinal - 3 to 4ml of 0.5% or 0.75% in adults. 0.3 to 0.5mg/kg of 0.5%
solution in children.
Peripheral nerve block – 15 to 30 ml of 0.15% to 0.5%. The toxic level is
reached when more than 2mg/kg of drug volume is used.
PHYSIOLOGY OF α2-ADRENOCEPTORS
α2 - receptors are found in multiple regions in our body. α2 adrenoceptors
are found in peripheral and central nervous systems. It is also present in major
organs like liver, kidney, pancreas, eye vascular smooth muscles and platelets.
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Physiologic responses facilitated by α2 adreno-ceptors differs with site and can
be the reason for multiplicity of their effects.
The classification of α2 - receptors based on anatomical site is complex
because these receptors are present in all regions like presynaptic, postsynaptic
and extrasynaptic. α2 - adrenoceptors are distributed into three subtypes; each
subtype is responsible uniquely for some of the actions of α2 - receptors.
 α2A is the main subtype commonly seen in CNS and is responsible for
the sedative, analgesic and sympatholytic effect.
 α2B is situated mainly in the peripheral vasculature and liable for the
short-term hypertensive response.
 α2C is found in the CNS and  in charge of the anxiolytic effect.
All the subtypes yield cellular action by signalling through a G-protein
which couples to effector mechanisms. This coupling differs based on the
receptor subtype and site its located. The α2A-adreno-ceptor subtype couple in
an inhibitory manner to the calcium channel in the locus ceruleus of the
brainstem, whereas in the vasculature the α2B-adrenoceptor sub type couple in
an excitatory mode to the same effector mechanism.
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Figure 1: Physiology of Alpha 2adrenergic receptors
PHARMACOLOGY OF CLONIDINE HYDROCHLORIDE
Introduction:
Clonidine hydrochloride is a centrally acting selective partial alpha 2
agonist first discovered in early 1960s. Its anti-hypertensive property was
found out after only after it was initially tried as nasal decongestant.
Subsequently more detailed study into the pharmacological properties has
helped us know its use in in clinical anaesthesia procedures as well.
It is an imidazoline compound. The chemical name is 2-(2,6-
dichlorophenylamino)-2 imidazoline  hydrochloride. The molecular weight is
266.56.  Clonidine is basically an odourless, bitter, white, crystalline substance
23
which is soluble in alcohol and water. Clonidine increases the quality of
anaesthesia and helps in giving us a steady cardiovascular status during
anaesthesia probably due to their sympatholytic effect. Hence it also decreases
dose requirement of the anaesthetic agent during surgery. Clonidine lessens the
halothane MAC by up to 50% in a dose dependent fashion. Clonidine also
improves the anaesthetic action of the local anaesthetics with lesser unwanted
effects in peripheral nerve blocks and in central neuraxial blockade.
Mechanism of action:
Clonidine is a centrally acting partial α2 adrenergic agonist with a
selectivity ratio of 220: 1 in favour of α2 receptors. When clonidine is injected
into epidural space it is crosses the blood brain barrier and reach the
hypothalamus and medulla. It also arouses the inhibitory α2 adrenergic
receptors to decrease the central neural conduction in the spinal neurons.
The α2 adrenoreceptors are densely found in the locus ceruleus, which
is an important part of sympathetic nervous system innervation of the forebrain.
Clonidine is an inhibitor of pontine locus ceruleus as it excites the α2
adrenergic neurons in the medullary vasomotor centre, which ends up in
decreasing the sympathetic nervous system transmission from central nervous
system to peripheral tissues. The decrease in sympathetic nervous system
outflow is mainly due to peripheral vasodilatation and leads to reduction in BP,
HR and cardiac output.
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Clonidine also decreases the anaesthetic requirement during surgical
procedure and additionally its analgesic effects too, the main mechanism
behind this is alteration of the potassium channels in the central nervous system
and hyperpolarisation in the cell membranes. Another influence to analgesic
effect may be due to the release of acetylcholine in the neuraxial region. The
α2 adrenergic agonist also augment analgesia from intra-spinal opioids. Its
action on locus ceruleus is one of the reason behind sedation.
The α2 adrenoreceptors terminals which are present centrally and
peripherally in superficial laminae of the spinal cord and brain stem nuclei is
supposed to be involved in analgesic effects after neuraxial administration of
clonidine. Similarly it also decreases the threshold for cold response and rises
the threshold for sweating by inhibition of the shivering response.
Clonidine also has effect on blood pressure in a multifaceted manner
after neuraxial or systemic administration. In the nucleus tractus solitarius and
locus ceruleus of the brain stem, activation of post-synaptic α2 adrenoreceptors
reduces the sympathetic actions which causes fall in BP and causes an anti-
arrythmogenic action.
Further in peripheral nerves it produces a minimal blockade at high
concentrations with a penchant for C- fibres and this effect also augments the
peripheral nerve block when given along with local anaesthetics, probably
because the α2 - adrenoreceptors are lacking on the axons of peripheral nerves.
Pharmacokinetics:
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Clonidine is well absorbed orally and bioavailability of clonidine is 75
to 95%. Its peak plasma half-life is about 60 to 90 minutes whereas mean
plasma half-life is 33 mins. 50% of the drug is mainly metabolized in the liver
while clonidine is excreted in an unchanged form by the kidney. A transdermal
delivery system is available in which the drug is released at a constant rate for
a week. Three or four days are required to achieve steady state concentration
in this case.
DOSAGE FOR DIFFERENT ROUTES:
Oral: 3-5μg/kg.
Intramuscular: 2 μg/ kg.
Intravenous: 1-2μg/kg.
Spinal: 1-2μg/kg.
Caudal: 1-2μg/kg.
Epidural: 1-2μg/kg.
Transdermal: 0.1-0.3 mg released per day.
PRECAUTIONS:
In patients with chronic kidney disease dose reduction is required. While
there is sudden withdrawal after a prolonged continuous epidural infusion
causes hypertensive crisis. So dose should be tapered slowly and should be
discontinued after 2 to 4 days to prevent the crisis. Should be carefully used in
patients with cerebrovascular or coronary insufficiency. Another important
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thing is if the patient is on beta blockers then it should be withdrawn several
days before the epidural clonidine.
CONTRAINDICATIONS:
 Known hypersensitivity to clonidine or components of the product.
 Brady arrhythmia or AV block.
 Severe cardiovascular disease.
 Cardiovascular / hemodynamic instability.
INTERACTIONS:
Clonidine sometimes augment the CNS- depressive effect of alcohol,
barbiturates or other sedative drugs. Clonidine also potentiate the hypotensive
action along with opioids. TCA antagonize the hypotensive effects of
clonidine. Concomitant administration of drugs with a negative chronotropic
or dromotropic effect can cause or potentiate bradycardia and rhythm disorders.
Beta blockers may augment the hypertensive response seen with clonidine
withdrawal.
USES:
Caudal anaesthesia:
1 to 2 μg/kg of clonidine combined with local anaesthetic agents
lengthen the duration of analgesia by 2 or 3 times without hemodynamic side
effects.
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Epidural block:
Clonidine as sole agent or along with opioids or local anaesthetics to
provide exceptional analgesia in labour analgesia.
Spinal anaesthesia:
Clonidine along with local anaesthetics increases the quality and
duration of the block, decreases the tourniquet pain during lower limb surgery,
and also prevents shivering.
Other uses:
 Pre anaesthetic medication: Oral clonidine is 5 micg/kg.
 Dampens reflex tachycardia linked with direct laryngoscopy for
intubation of trachea.
 Decreases the intraoperative fluctuation of the blood pressure and heart
rate.
 Plasma catecholamine levels are reduced.
 Intensely reduces anaesthetic requirements of inhaled and injected
drugs.
 In Peripheral nerve blocks Clonidine increases the duration of
anaesthesia and analgesia along with local anaesthetics by two times.
 In Bier’s Block: 150 microgram of clonidine enhances the tolerance of
tourniquet.
 It is also useful in intra articular analgesia.
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 Protection against perioperative myocardial ischemia: Clonidine
decreases myocardial ischemia, infarction and mortality following
cardiovascular surgery.
 In the management of hypertensive crisis clonidine is useful.
 Treatment of shivering; Administration of clonidine -75μg IV abolishes
shivering by inhibiting thermoregulatory control.
 Clonidine is also useful in the management of opioid and alcohol
withdrawal syndrome.
Side effects;
The most common side effects are sedation and xerostomia.
Cardiovascular complications are bradycardia, hypotension, and sinus node
arrest, high degree AV block and other arrhythmia are reported rarely.
Orthostatic hypotension occurs rarely.
Rebound hypertension; Sudden stoppage of clonidine can end up in rebound
hypertension as soon as 8 hrs and as late as 36 hrs after the last dose. Symptoms
of the rebound hypertension is headache, abdominal pain, tachycardia,
nervousness, and diaphoresis, which often precede the actual increase in
systemic blood pressure. Labetalol is useful in this situation.
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DEXMEDETOMIDINE
Dexmedetomidine is a recently introduced highly selective alpha 2
adrenergic receptor agonist that has sedative and analgesic sparing effects,
decreased delirium, agitation and perioperative sympatholysis, stable
cardiovascular system maintainence, decreased requirement of anaesthetics
and also helps in maintaining respiratory function. Dexmedetomidine is a quite
a new drug approved by FDA in 1999 for human use for short term sedation
and analgesia in ICU
Chemical structure:
Dexmedetomidine is the dextrorotatory S-enantiomer of
medetomidine. It is chemically (S)-4-[1-(2,3-dimethylphenyl) ethyl]-3H-
imidazole
MECHANISM OF ACTION:
α2- AR agonists produce clinical effects after binding to G-Protein-
coupled α2-AR. There are three subtypes (α2A, α2B, and α2C) with each
subtype having diverse physiological role and pharmacological actions. These
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receptor subtypes are found all over in the central, peripheral and autonomic
nervous systems, as well as in vital organs and blood vessels.
Dexmedetomidine is more selective towards α2-AR than clonidine by at least
8-10 times. Neither clonidine nor dexmedetomidine is absolutely selective for
any one of the α2-AR subtypes, but dexmedetomidine seems to have more
α2A- AR and α2C-AR affinity than clonidine.
COMPARISON OF CLONIDINE WITH DEXMEDETOMIDINE
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Locus ceruleus of the brain stem is the primary region site for the
sedative action and spinal cord is the main site for the analgesic action, both
exerts their action through α2A-AR. In the heart, the main action of α2-AR
agonists is a reduction in incidence of tachycardia by blocking cardio-
accelerator nerve and bradycardia through α2A-AR primarily through a
vagomimetic action. Where as in the peripheral vasculature, there is
sympatholysis - mediated vasodilatation and also smooth muscle cells receptor
particularly EGFR-mediated vasoconstriction.[8] The mechanism for the anti-
shivering and diuretic actions has yet to be established definitely[9]
The reactions to stimulation of the receptors in other sites further causes
reduced salivation, secretion, and bowel motility; further the contraction of
vascular and other smooth muscles are also reduced; In kidney it causes renin
release inhibition, glomerular filtration rate is also increased, and hence there
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is rise in secretion of sodium and water in the kidney; IOP is reduced and
insulin release is also reduced.
PHARMACOKINETICS:
Absorption and distribution
Dexmedetomidine displays linear pharmacokinetics in dose range of 0.2
to 0.7 μg/kg/ hr when infused in intravenous route for 24 hrs. The distribution
phase is rapid, with a distribution half-life of 6 minutes and elimination half-
life of 2 hours. The apparent volume of distribution (Vd) is 118 L. It has 94%
plasma protein binding capacity. It has insignificant protein binding
displacement by drugs frequently used during anaesthesia like fentanyl,
ketorolac, theophylline, digoxin, and lidocaine. It has poor bioavailability in
oral route due to high first-pass metabolism. Whereas when administered
sublingually bioavailability is high (84%), hence it’s useful in paediatric
sedation and premedication.
Metabolism and excretion
Dexmedetomidine endures complete biotransformation through direct
N-glucuronidation and cytochrome P-450 (particularly CYP 2A6)-mediated
aliphatic hydroxylation and converted to inactive metabolites. Metabolites are
mainly excreted via urine (95%) and in the faeces (4%). Dose reduction may
be required in patients with hepatic failure.
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Action on Cardiovascular system
Dexmedetomidine evokes a biphasic response on blood pressure,
initially an short hypertensive phase followed by hypotension. They are
mediated by α-2B AR and α2A-AR respectively. In patient who have increased
vagal tone particularly in younger age group bradycardia and sinus arrest have
been seen which were treated with anticholinergic agents like atropine,
glycopyrrolate.
Central nervous system
Dexmedetomidine decreases cerebral blood flow and cerebral metabolic
need of oxygen but its action on intracranial pressure (ICP) is not yet explained
clearly. Dexmedetomidine modifies spatial working memory, increasing the
cognitive performance apart from having sedative, analgesic, and anxiolytic
effects. Previous researchers have suggested the possibility of its
neuroprotective action by decreasing circulating and brain catecholamine’s
levels and therefore maintains the cerebral oxygen supply, decreasing
excitotoxicity, and increasing perfusion in the ischemic penumbra. It also
decreases the glutamate level which are particularly liable for cellular brain
injury, particularly in SAH.
Effect on Respiratory system
Dexmedetomidine basically doesn’t subdue the respiratory function,
even at higher dose range. It helps assists in sustaining sedation without causing
any cardiovascular instability or depression of respiratory drive and simplify
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weaning and extubation in ICU patients who have negative attempts at weaning
due to agitation and hyperdynamic cardiopulmonary response.
Endocrine and renal effects
Dexmedetomidine triggers peripheral presynaptic α2- AR which decreases the
release of catecholamines, and hence lessens sympathetic response to surgery.
Animal studies have demonstrated the occurrence of natriuresis and diuresis.
ADVERSE EFFECTS
 Blood pressure abnormalities
 Nausea
 Vomiting
 Dry mouth
 Bradycardia
 Atrial fibrillation
 Pyrexia and chills
 Pleural effusion
 Atelectasis
 Pulmonary oedema
 Hyperglycaemia
 Hypocalcaemia
 Acidosis.
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Rapid administration of dexmedetomidine infusion (Loading dose of 1
μ/ kg/ hr if given in less than 10 minutes) may end up in transient hypertension
mediated mainly by α2B- AR induced vasoconstriction. But hypotension and
bradycardia may happen with ongoing therapy mediated by central α2A-AR,
causing decreased release of noradrenaline from the sympathetic nervous
system. Dexmedetomidine when used for longer periods causes super
sensitization and upregulation of receptors; hence when there is sudden
stoppage there develops a withdrawal syndrome with symptoms like
nervousness, agitation, headaches, and hypertensive crisis can happen. FDA
has categorised dexmeditomedine in category C pregnancy risk, so the drug
should be used with extreme caution in women who are pregnant.
CLINICAL USES:
Dexmedetomidine is primarily used as an adjuvant for premedication,
particularly in patients who has high tendency for preoperative and
perioperative stress, the rationale behind this is because of its sedative,
anxiolytic, analgesic, sympatholytic, and stable hemodynamic properties.
Dexmedetomidine reduces oxygen requirement up to 8 percent in
intraoperative period and up to 17 percent in postoperative period.
Premedication dose is 0.33 to 0.67 mg/kg IV given 15 minutes before surgery,
this helps in reducing the unwanted effects like hypotension and bradycardia.
Intraoperatively Dexmedetomidine reduces hemodynamic stress
reaction to intubation and extubation by causing sympatholysis. As it has no
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effect on respiratory depression, it can be sustained up to extubation period
which is not seen in other similar drugs. Dexmedetomidine improves
anaesthetic effect of all the anesthetic agents regardless of the route of
administration. Intraoperative infusion of dexmedetomidine in lesser
concentrations has decreased the need of other anaesthetic agents; need of
treating tachycardia were reduced; and there is significant decrease in the
incidence of myocardial ischemia. But adverse effects like bradycardia and
hypotension are limitations of this drug. These effects may be due to the
combined properties of volatile anaesthetics such as vasodilatation and
myocardial depression. Dexmedetomidine administered in higher dosage may
cause systemic and pulmonary hypertension due to its direct peripheral
vascular actions.
High lipophilic nature of dexmedetomidine causes quick absorption into
the cerebrospinal fluid and binding to α2-AR of spinal cord for its analgesic
property. It increases the duration of both sensory and motor blockade
produced by local anaesthetics regardless of the mode of administration.
Dexmedetomidine though enhances both central and peripheral neural
blockade caused by local anesthetics; Dexmedetomidine is also used in
intravenous regional anesthesia (IVRA), brachial plexus block, and intra-
articularly for some conditions. Adding 0.5 μg/kg dexmedetomidine to
lidocaine for IVRA increases quality of anesthesia and increases intraoperative
and postoperative analgesia without causing any unwanted effects.
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Dexmedetomidine when given along with levobupivacaine for axillary brachial
plexus block decreases the onset time of analgesia and increases the period of
the block and postoperative analgesia. When given through intra-articular route
particularly in patients undergoing arthroscopic knee surgery
dexmeditomedine increases the quality and duration of postoperative analgesia.
Dexmedetomidine of the late has become widespread sedative agent
used in ICU due to its ability to cause co-operative sedation, i.e., patients
remain awake, calm, and are able to converse their needs. It also neither cause
any change in respiratory drive nor produce any agitation, hence helps in early
extubation, thereby decreasing overall ICU stay costs. Also the maintenance of
natural sleep during sedation helps in quickening the recovery.
Dexmedetomidine currently is approved by FDA for use in ICU for not more
than 24 hours. Dexmedetomidine, when compared with conventional sedatives
and opioids has a better sedative and analgesic sparing effects, decreased
delirium and agitation, very less chance for respiratory depression, and has
anticipated cardiovascular effects.
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Dexmedetomidine is a pretty good drug for short-term procedural
sedation and is used commonly in transoesophageal echocardiography,
colonoscopy, awake carotid endarterectomy, shockwave lithotripsy,
vitreoretinal surgeries, fiber-optic intubation, in paediatric patients for
procedure like tonsillectomy, and paediatric MRI. The best dose of
dexmedetomidine for procedural sedation is 1 μg/ kg, followed by an infusion
of 0.2 μg/kg/h. Time taken for onset of action is less than 5 minutes and the
peak effect occur by 15 minutes.
Dexmedetomidine is an effective and safe agent for controlled
hypotension facilitated by its central and peripheral sympatholytic property. Its
easy administration, liability with other anaesthetic agents, and minimal
adverse effects while also sustaining sufficient perfusion of the vital organs
makes it a near-ideal hypotensive agent. Procedures like spinal fusion surgery
for idiopathic scoliosis, septoplasty and tympanoplasty operations, and
maxillofacial surgery have been safely done with dexmedetomidine-controlled
hypotension.
Dexmedetomidine stimulates α2-AR in the spinal cord decreasing
transmission of nociceptive signals like substance P. It has substantial opioid
sparing effect and is beneficial in intractable neuropathic pain.
Dexmedetomidine apart from decreasing the hemodynamic response to
endotracheal intubation also decreases the incidence of myocardial ischemia
during cardiac surgery. Hence dexmedetomidine has been efficaciously used
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to manage patients with pulmonary hypertension who undergoes mitral valve
replacement, because it decreases main parameters like pulmonary vascular
resistance, pulmonary artery pressure, and pulmonary capillary wedge
pressures.
In neurosurgical cases dexmedetomidine offers us unwavering cerebral
hemodynamics without sudden rise in ICP during intubation, extubation, and
head pin insertion. It decreases neurocognitive impairment thereby allowing
immediate postoperative neurological evaluation. It applies its neuroprotective
effects through multiple mechanisms which make the usage of this drug a
favourable tool during cerebral ischemia. It also has a very bright upcoming
role in “functional” neurosurgery. This includes awake craniotomy for the
resection of tumours or epileptic foci in eloquent areas, and the implantation of
deep brain stimulatorsin patients suffering Parkinson's disease.
In Obstetrics dexmedetomidine has been effectively used as an adjunct to
inadequate analgesia by systemic opioids in labouring parturient who could not
benefit from epidural analgesia.[50] It also offers maternal hemodynamic
stability, anxiolysis, and prompting uterine contractions. It crosses placental
barrier very minimally into the foetal circulation when compared to clonidine
because of high lipophilicity and thereby has less susceptibility to cause fetal
bradycardia.
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OTHER USES
 The literature also suggests other potential uses for
dexmedetomidine like in the treatment of withdrawal from
benzodiazepines, opioids, alcohol, and recreational drugs.
 As an adjunct in otorhinolaryngology anaesthesia for middle ear
surgery and rhinoplasty.
 As an adjunct in the repair of aortic aneurysms.
 Management of tetanus in ICU.
 As an antishivering agent.
 Dexmedetomidine is also effective in preventing ethanol-induced
neurodegeneration.
Hence dexmedetomidine because of its distinctive properties offers its
promising use in wide spectrum of clinical settings and ICUs. It is a part of
fast-tracking anaesthesia regimens and offers anaesthetic sparing and
hemodynamic stabilizing effects. As pharmacological effects of
dexmedetomidine can be reversed by α2-AR antagonist atipamezole,
combination of dexmedetomidine and atipamezole can provide titratable form
of sedation in the future.
Based on these detailed learning about above said drugs we did a review
of various studies
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In one of study done by Dhurjoti prosad et al. where he did a research on
90 pediatric surgery patients where caudal analgesia was used in age group
between one to six years and divided them into three groups. Ropivacaine in
0.25% concentration and dose of 1 ml/kg was given in all three groups of
patients while group C received clonidine  1 mcg/kg and  group D received
dexmedetomidine1mcg/kg. The study was supportive with the adjuvants where
the mean duration of analgesia was 6 ± 0.46 hrs in Group R, Patients given
clonidine has mean duration of analgesia as 13.17 ± 0.68 hrs and Group D
15.26 ± 0.86 hrs. Addition of dexmedetomidine and clonidine with ropivacaine
in caudal anaaethesia has a better analgesic effect compared to when
ropivacaine given alone and also there was no signs of hemodynamic
instability.
In one another study done by Saadway et al, they analyzed outcome of
dexmedetomidine given along with bupivacaine in caudal anaesthesia in
pediatric age group. This study revealed that there was exceptional
intraoperative and postoperative analgesia and with minimal adverse effects.
Abd  Elwahab et al did a research work in 60 patients who were
randomly selected between 6 months to six years of age who underwent infra
umbilical  surgeries. Patients were seperated into two groups. Group C received
bupivacaine 0.25% 1ml/kg along with clonidine at 2 mcg/kg dose and Group
D received bupivacaine 0.25% 1ml/kg along with dexmedetomidine at 2
mcg/kg dose as caudal anesthesia. The study result revealed dexmedetomidine
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group had prolonged duration of post-operative analgesia in comparison with
clonidine group, without any noteworthy side effects.
Thomas et al did a double blind randomized controlled study were
patients were divided into three groups, clonidine at dose of 2 mcg/kg,
morphine at dose of 50 mcg/kg, hydromorphine at dose of 10 mcg/kg with
0.25%of ropivacaine in adrenaline as common drug used in all three groups.
Results revealed that clonidine when give along with ropivacaine as adjuvant
significantly increased duration of analgesia without any important adverse
effects. Caudal opioid produced the postoperative nausea and vomiting which
was not seen with clonidine.
Nursel et al did a comparison between clonidine and ketamine with
ropivacaine as common drug in caudal anesthesia for children, this was done
as a randomized controlled study divided into three groups. Group R is received
0.75ml/kg of 0.25% ropivacaine alone. Group RC received 0.75ml/kg of 0.25%
ropivacaine with 2 mcg/kg clonidine and Group RK is received 0.75ml/kg of
0.25% ropivacaine along with ketamine 0.5mg/kg. All three groups were
monitored for plasma insulin, blood glucose, serum cortisol, sedation levels
and complications if any. Results of this study revealed clonidine and ketamine
group helps in increasing duration of analgesia and decreasing the stress
response to surgery.
Erbek et al did a randomized comparative study between bupivacaine
0.5% and dexmedetomidine sedation for septoplasty procedure especially. The
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patients were separated and randomized into two groups. Group B patients
received 0.5% bupivacaine alone and group BD patients received 0.5%
bupivacaine along with dexmedetomidine 2mcg/kg. The study results were in
such way that bupivacaine when combined with dexmedetomidine is superior
for both intraoperative and postoperative pain relief and also helps in
decreasing the intraoperative bleeding than when bupivacaine given alone.
Jabir kaur et al. did a research work to decide the quantitative and
qualitative effect of caudal epidural anesthesia, hemodynamic effects and
postoperative duration of analgesia when clonidine is used as adjuvant. This
study was done as randomised controlled double blind study in children of age
between 1-9 years who were divided into two group, group I received 0.25%
of ropivacaine and group II received 0.25% of ropivacaine along with clonidine
2 mcg/kg .This study also had similar results like above studies where duration
of post-operative analgesia is prolonged in group II where clonidine was added
and proficient intraoperative analgesia was maintained without any significant
hemodynamic changes.
Deepanjali pant et al did a study in Indian population in 40 children who
were randomly selected and evaluated for caudal clonidine analgesic effects,
along with hemodynamic effects and respiratory status of the children in day
care pediatric surgeries. Children’s were divided into the two groups. While
children in group B received 0.25%of bupivacaine and children in group C
received 0.25% of bupivacaine with clonidine 2 mcg/kg. Postoperative
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monitoring of objective pain scale score, sedation score, pulse rate and blood
pressure were done. This study revealed that the duration of analgesia in
patients on clonidine with bupivacaine was 10.25 hours when compared with
patients on bupivacaine alone was 4.55 hours and there wasn’t any
hemodynamic instability.
N Kumar et al did a randomized controlled prospective study 50 patients
who underwent upper abdominal surgeries were divided into two groups. One
group of patients received 0.25% of bupivacaine 1.25 ml/kg along with
morphine 30mcg/kg and another group was administered 0.25% of bupivacaine
1.25 ml/kg along with clonidine 2 mcg/kg. In this study the results concluded
patients on clonidine had prolonged duration of post-operative analgesia than
patient who were given morphine. The morphine group was produced more
nausea and vomiting when compared to patients on clonidine.
Korkmaz F et al also did a randomized, prospective, controlled study for
prolong duration of analgesia for caudal clonidine combined with isobaric
bupivacaine. Totally 60 children was selected and divided into the two groups.
Group B are received 1ml/kg of 0.125% isobaric bupivacaine and group BC
are received 1ml/kg   of 0.125% isobaric bupivacaine along with 2mcg/kg of
clonidine. This study results revealed that the duration of analgesia prolonged
in patients who were administered bupivacaine with clonidine without
significant hemodynamic instability during intraoperative and postoperative
periods.
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Vijay anand G et al did a prospective, randomized controlled, double
blind study in which comparison of 0.25% of isobaric ropivacaine with and
without  dexmedetomidine who underwent lower abdominal surgeries in 60
children of age between six months to six years.  Group R received 0.25% of
ropivacaine 1ml/kg and group RD received 0.25% of ropivacaine 1ml/kg along
with dexmedetomidine 2 mcg/kg. Conclusion of this study was such that the
duration of postoperative analgesia in group RD was 14.5 hours compared to
group R in which it was 5.5 hours without any hemodynamic instability.
Sukmindher jit et al conducted a study to compare two α- 2 adrenergic
agonists dexmedetomidine and clonidine in epidural anaesthesia. A prospective
randomized trial was carried out which included 50 adult female who
underwent vaginal hysterectomies. The patients were randomly assigned into
two groups as below ropivacaine + dexmedetomidine (RD) and ropivacaine +
clonidine (RC). Onset of analgesia, sensory and motor block levels, sedation,
duration of analgesia and side effects were observed. Sedation scores were
better with dexmedetomidine than clonidine and based on the results it was
concluded that dexmedetomidine is a better neuraxial adjuvant than clonidine
for providing early onset of sensory analgesia, adequate analgesia and a
prolonged post-operative analgesia.
Ashraf et al did a work to evaluate the analgesic assets of
dexmedetomidine alone or as adjuvant with bupivacaine 0.125% when given
as an epidural infusion for the management of postoperative pain in patients
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who underwent extensive abdominal surgery. 90 adult patients were studied.
Patients were randomly divided into three groups to receive an epidural
infusion at 10 mL/h of bupivacaine 0.125% in group B, dexmedetomidine 0.5
μg/kg/hr in bupivacaine 0.125% in group DB and dexmedetomidine 0.5
μg/kg/hr diluted in 0.9% saline in Group D. VAS score, sedation score, sensory
and motor blockade, MAP and HR were observed and recorded. Rescue
analgesia was given in the form of patient controlled analgesia and the total
analgesic needed were recorded. The Group DB had minimal need of
analgesics and also duration of analgesia was longer in comparison with Group
B. VAS were similar for all groups. MAP and HR were similar in groups (D
and DB), both were significantly lower than in Group B with P value less than
0.05. Whereas the motor block was more significant in-group B and DB
compared with group D in the PACU and up to 6 h post infusion.While sensory
blockade was more pronounced in the DB group. This study proved that in
patients undergoing extensive abdominal surgeries adding dexmedetomidine
to epidural infusions of bupivacaine considerably increases postoperative
analgesia without any significant adverse effects.
Another study done by Antonio et al to assess the analgesia and sedation
effect by clonidine or dexmedetomidine when given along with epidural
ropivacaine during postoperative period of patients undergoing subcostal
cholecystectomy. 40 patients of both sex were included in this randomized
double-blind study. The patients were allotted in 2 groups: Group CG received
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clonidine (1 mL = 150 μg) along with 20 ml of 0.75% epidural ropivacaine,
Group DG received dexmedetomidine (2 μg/kg) along with 20 ml of 0.75%
epidural ropivacaine. Analgesia and sedation were assessed at 2, 6 and 24 hours
after anaesthetic recovery. This study revealed better analgesic effect with
dexmeditomedine.
Taylor et al evaluated the properties of epidural ketamine, clonidine and
dexmedetomidine, in patients undergoing upper abdominal surgery. This study
was done as a randomized double-blind study in patients of both genders.
Lumbar epidural anaesthesia was randomly administered as follows with
control group receiving 20 mL of 0.75% ropivacaine and 1 mL of 0.9% saline
solution; Ketamine group receiving 20 mL of 0.75% ropivacaine and 0.5 mg/kg
ketamine whereas clonidine group received 20 mL of 0.75% ropivacaine and 1
mL clonidine (150 μg) (n = 20) and dexmedetomidine group received 20 mL
of 0.75% ropivacaine and 2 μg/kg dexmedetomidine. Analgesia was assesed
by clinical signs and inhalational anaesthetic inspired concentration was
evaluated by anaesthetic gases analysis during surgery. All patients receiving
ketamine, clonidine or dexmedetomidine had reduced heart rate and systemic
blood pressure and did not needed perioperative analgesic complementation.
Hennaway et al the analgesic effects and adverse effects of
dexmedetomidine and clonidine added to bupivacaine in paediatric patients
who underwent lower abdominal surgeries. 60 patients were randomly
assigned into three groups in a double-blinded manner. Each patient was
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administered a single caudal dose of bupivacaine 0.25% (1 ml/kg) combined
with either dexmedetomidine 2 μg/kg in normal saline 1 ml, clonidine 2 μg/ kg
in normal saline 1 ml, or corresponding volume of normal saline.
Hemodynamic variables, end-tidal sevoflurane, and emergence time were
monitored. Postoperative analgesia, use of analgesics, and ADR profile were
evaluated during the first 24 h. Addition of dexmedetomidine or clonidine to
caudal bupivacaine considerably increased duration of analgesia than the use
of bupivacaine alone. However, there was no statistically significant difference
between dexmedetomidine and clonidine as regards the analgesia time in that
study, also there was neither any significant difference in hemodynamic
changes or ADR profile.
Neogi et al did a randomized prospective study to evaluate the efficacy
of clonidine and dexmedetomidine when used as adjuvant to ropivacaine for
caudal analgesia in paediatric patients. 75 patients undergoing elective inguinal
herniotomy were included in the study. Patients were allocated into three
groups, Group R patients received 1 ml /kg of 0.25% ropivacaine caudally.
Group C patients received 1ml kg-1 of 0.25% ropivacaine along with 1ml / kg
clonidine. And patients of group D were given 1 ml/ kg of 0.25% ropivacaine
along with 1 μg.kg-1 dexmedetomidine. Postoperative analgesia was evaluated
by CRIES scale. The mean duration of analgesia was 6.32±0.46 hours in group
R, 13.17±0.68 hours in group C and 15.26±0.86 hours in group D. The
prolongation of duration of analgesia was significant in both groups C and D
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in comparison to group R. This study proved that addition of both clonidine
and dexmedetomidine with ropivacaine administered caudally significantly
increase the duration of analgesia.
Based on above studies it is pretty much clear that both clonidine and
dexmeditomedine have a positive effect on duration of analgesia and
haemodynamic stability, but not much study has been done to evaluate the
difference in these two groups particularly when given as epidural analgesia in
adults undergoing surgery for inguinal hernia when ropivacaine is given as
primary agent. Hence our aim is to evaluate the difference between these two
drugs on various factors during analgesia.
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MATERIALS AND METHODS
This study was conducted at Tirunelveli medical college hospital,
Tirunelveli from 2017-2018 for a period of one year after obtaining approval
from hospital institutional ethical committee.
METHODOLOGY:
Study design : Prospective randomised double blinded interventional study
Sample size : 60 adult male patients to be selected that will be divided in to
2 groups with 30 patients in each group
Inclusion criteria:  Adult male patients with height 155 to 170 cms and Age
between 40 to 60 yrs with ASA physical status I and II who are to undergo
surgery for inguinal hernia.
Exclusion criteria:
Patients having bleeding and coagulation disorder, Hypertension, Cardiac
disease, Infection at the epidural site, Hepatic and renal diseases, severe
anaemia.
Pre-operative visit:
In all patients, age, body weight and baseline vital parameters were recorded.
History regarding previous anaesthesia, surgery and significant other co
morbid illness, medications and allergy was recorded. Complete physical
examination and airway assessment were done. In the preoperative period all
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patients were instructed about the benefits of epidural analgesia and 10-point
visual analogue scale. And also informed consent form was obtained from all
the study group patients.
Premedication:
All patients were premedicated with Inj. Metaclopramide 10mg and
Inj.Ranitidine 50 mg im 45 minutes before surgery.
Monitors attachment and intravenous access:
Standard monitors like ECG, Non-invasive BP, and spO2 were connected to
the patient. Intravenous access was done using 16 or 18 Gauge venflon and
intravenous crystalloid was started.
Epidural Catheterisation:
Prior to induction of anaesthesia under strict aseptic precaution an epidural
catheter tip was kept around T12-L1 intervertebral space in lateral position by
using 9 cm long, 18 gauge Tuohy’s needle by loss of resistance technique. The
epidural catheter position was rechecked with a test dose containing 3 ml of
1.5% lignocaine with adrenaline (5μg/ml).
Operational Procedure:
Patients will be administered lumbar epidural block with 18G touhy
needle, and catheter will be secured 3- 4 cm into the epidural space. Patients of
group I will receive 12ml of 0.75% ropivacaine plus 2 mcg/kg of clonidine.
Patients of group II will receive 12 ml of 0.75% ropivacaine plus 1.5mcg/kg of
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dexmedetomidine. Cold swab will be used to evaluate and check the sensory
level. Modified bromage scale will be used to measure the motor blockade at
5,10,15,20, 25 and 30 min from the time of epidural administration of drugs.
Surgical position will be made approximately 25 to 30 min after epidural
administration of drugs in every patient after complete establishment of
sensory and motor block.
The following variables were measured and compared
 Onset of analgesia,
 Duration of analgesia
 Heart rate
 Mean arterial pressure
 Intra operative and postoperative sedation score (ramsay
sedation scale)
 Post-operative pain (visual analogue score)
 Side effects like dry mouth, nausea, vomiting, headache,
shivering.
All the vital and hemodynamic parameters will be recorded intraoperatively
every 5 mins and postoperatively for fisrt 2 hrs at intervals of 30 min and at 4,
8,12,16,24 hrly intervals from the initial dose. The onset of postoperative pain
(VAS>5) will be managed by top up dose of 6 ml of 0.2% ropivacaine in the
post-operative room.
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STATISTICAL ANALYSIS
All the data will be compiled systematically and analyzed using
‘Analysis of variance, student t test and chi- square test. Statistical package for
social science (SPSS) version 21.0 was used to compare the continuous
variables between the two groups.
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RESULTS
AGE DISTRIBUTION
AGE (IN YEARS) NO OF PATIENTS PERCENTAGE
40-50 29 48%
51-60 31 52%
Range : 40-60 years
Mean age – 50.48 years
AGE (IN YEARS) DEXMEDITOMEDINE CLONIDINE
40-50 13 16
51-60 17 14
29
31
AGE DISTRIBUTION
40-50 51-60
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Patients less than forty years were most commonly administered clonidine
while it was opposite in age more than 40 yrs where dexmeditomedine was
commonly administered.
TYPE OF DRUG
TYPE OF DRUG NO OF PATIENTS PERCENTAGE
DEXMEDITOMEDINE 30 50%
CLONIDINE 30 50%
13
1716
14
0
5
10
15
20
41-50 51-60
AGE DISTRIBUTION
DEXMEDITOMEDINE CLONIDINE
50%50%
TYPE OF DRUG
DEXMEDITOMEDINE
CLONIDINE
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TYPE OF HERNIA
TYPE OF HERNIA NO OF PATIENTS PERCENTAGE
RIGHT INGUINAL HERNIA 39 65%
LEFT INGUINAL HERNIA 21 35%
Most of the patients were having right inguinal hernia with prevalence of 65%
among our study group.
TYPE OF HERNIA DEXMEDITOMEDINE CLONIDINE
RIGHT INGUINAL HERNIA 20 18
LEFT INGUINAL HERNIA 10 12
65%
35%
TYPE OF HERNIA
RIGHT INGUINAL HERNIA
LEFT INGUINAL HERNIA
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There was not much difference in type of drug used based on type of hernia.
HEMODYNAMIC PARAMETERS
BASELINE - DEXMEDITOMEDINE
PARAMETERS MEAN SD
HEART RATE 83.16 9.46
SYSTOLIC BP 123.33 11.36
DIASTOLIC BP 81.06 10.52
MAP 95.03 8.23
SPO2 98.83 0.74
20 19
10 1
1
D E XMED I TOMED INE C LON ID INE
TYPE OF HERNIA
RIGHT INGUINAL HERNIA LEFT INGUINAL HERNIA
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BASELINE - CLONIDINE
PARAMETERS MEAN SD
HEART RATE 81.26 10.8
SYSTOLIC BP 121.53 11.79
DIASTOLIC BP 78.6 7.39
MAP 93.2 7.71
SPO2 99.3 0.5
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BASELINE - MEAN COMPARISON
PARAMETERS DEXMEDITOMEDINE CLONIDINE P VALUE
HEART RATE 83.16 81.26 0.472
SYSTOLIC BP 123.33 121.53 0.55
DIASTOLIC BP 81.06 78.6 0.298
MAP 95.03 93.2 0.379
SPO2 98.83 99.3 0.107
There not significant difference in baseline value between both groups.
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HEART RATE
INTRA OPERATIVE - MEAN COMPARISON
HEART RATE DEXMEDITOMEDINE CLONIDINE P VALUE
0 MIN 78.06 85.93 0.001
5 MIN 80.26 76.46 0.063
10 MIN 73.06 80.2 0.001
15 MIN 73.2 80.4 0.004
20 MIN 73 79 0.002
25 MIN 71.2 74.33 0.143
30 MIN 71.2 77.56 0.004
45 MIN 74.6 74.4 0.926
60 MIN 76.06 74.66 0.541
75 MIN 69 76.53 0.011
90 MIN 80.2 77.26 0.195
Intra operative Heart rate there is difference in two drugs where heart rate
is comparatively higher in clonidine compared to that of dexmeditomedine. This
difference was analysed using unpaired t test and was statistically significant at
various time period.
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SYSTOLIC BLOOD PRESSURE
INTRA OPERATIVE - MEAN COMPARISON
SYSTOLIC BP DEXMEDITOMEDINE CLONIDINE P VALUE
0 MIN 129.2 133.46 0.101
5 MIN 112.53 103.33 0.001
10 MIN 124.46 108.73 0.001
15 MIN 123.33 110.73 0.001
20 MIN 122.53 110.6 0.001
25 MIN 122.86 110.73 0.001
30 MIN 123.46 111.06 0.001
45 MIN 125 113.13 0.001
60 MIN 126.53 120.26 0.001
75 MIN 125.6 120.66 0.001
90 MIN 124.4 121.66 0.033
Intra operative systolic BP there is difference in two drugs where SBP is
comparatively lower in clonidine compared to that of dexmeditomedine. This
difference was analysed using unpaired t test and was statistically significant at
various time period.
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DIASTOLIC BP
INTRA OPERATIVE - MEAN COMPARISON
DIASTOLIC BP DEXMEDITOMEDINE CLONIDINE P VALUE
0 MIN 84.06 82.66 0.483
5 MIN 76.93 62.4 0.001
10 MIN 82 67.46 0.001
15 MIN 80.4 69.46 0.001
20 MIN 80.73 69.13 0.001
25 MIN 78.06 68.86 0.001
30 MIN 77.06 73.53 0.008
45 MIN 79.66 75.33 0.003
60 MIN 79.46 78.13 0.333
75 MIN 78.73 79.6 0.466
90 MIN 77.06 80.66 0.003
Intra operative diastolic blood pressure there is difference in two blocks
where DBP is comparatively lower in clonidine compared to that of
dexmeditomedine. This difference was analysed using unpaired t test and was
statistically significant at various time period except at 0 and 60 min.
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MEAN ARTERIAL PRESSURE
INTRA OPERATIVE - MEAN COMPARISON
MAP DEXMEDITOMEDINE CLONIDINE P VALUE
0 MIN 98.56 99.26 0.692
5 MIN 88.4 75.73 0.001
10 MIN 95.9 80.9 0.001
15 MIN 94.36 82.47 0.001
20 MIN 94.33 80.26 0.001
25 MIN 92.93 82.43 0.001
30 MIN 92.16 85.6 0.001
45 MIN 94.43 87.36 0.001
60 MIN 94.53 91.83 0.012
75 MIN 94.2 93.03 0.248
90 MIN 92.56 93.96 0.154
Intra operative mean arterial pressure there is difference in two drugs
where MAP is comparatively lower in clonidine compared to that of
dexmeditomedine. This difference was analysed using unpaired t test and was
statistically significant at various time period except at later stages after 60 minutes.
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Spo2
INTRA OPERATIVE - MEAN COMPARISON
SPO2 DEXMEDITOMEDINE CLONIDINE P VALUE
0 MIN 99.06 99 0.534
5 MIN 98.96 99 0.661
10 MIN 98.9 99 0.179
15 MIN 99 99 1
20 MIN 98.96 99 0.661
25 MIN 98.93 99 0.42
30 MIN 98.86 99 0.039
45 MIN 98.73 99 0.002
60 MIN 98.73 99 0.002
75 MIN 98.7 99 0.001
90 MIN 99 99 1
There is not much difference in Spo2 of two groups intraoperatively except
at later stages which is also not a massive difference to consider as an impact.
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VISUAL ANALOGUE SCALE
VISUAL ANALOGUE SCALE
TIMELINE DEXMEDITOMEDINE CLONIDINE P VALUE
0 HRS 0 0 NIL
0.5 HRS 0 0 NIL
1 HRS 0 0 NIL
1.5 HRS 0 0 NIL
2 HRS 0 0.93 0.001
2.5 HRS 0.9 1 0.078
3 HRS 0.9 1 0.001
3.5 HRS 0.9 2.9 0.001
4 HRS 1.96 3 0.001
4.5 HRS 1.96 3 0.001
5 HRS 1.96 3 0.001
5.5 HRS 1.96 3 0.001
6 HRS 2.23 3 0.001
10 HRS 2.2 3 0.001
14 HRS 2.03 3 0.001
18 HRS 2.03 3 0.001
22 HRS 2.03 3 0.001
24 HRS 2.06 3.067 0.001
In Visual analogue scale, dexmeditomedine has a reduced pain score over
of a time period of 24 hours. which is also statistically significant. Also pain appears
earlier in clonidine group comparatively which is statistically significant.
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HEART RATE
POST OP - MEAN COMPARISON
HEART RATE DEXMEDITOMEDINE CLONIDINE P VALUE
0 HRS 80.4 77.2 0.138
0.5 HRS 79.86 73.4 0.003
1 HRS 78.86 79.1 0.917
1.5 HRS 75.13 76.6 0.458
2 HRS 77.33 74.26 0.155
2.5 HRS 76 78.76 0.201
3 HRS 78.4 78.03 0.86
3.5 HRS 78.2 76.26 0.383
4 HRS 79.2 76.43 0.202
4.5 HRS 79.6 76 0.132
5 HRS 78.83 75.03 0.101
5.5 HRS 76.13 75.66 0.829
6 HRS 78.36 74.93 0.111
10 HRS 75.6 76.5 0.701
14 HRS 75.36 77.96 0.259
18 HRS 73.93 74.8 0.673
22 HRS 76.5 76.4 0.96
24 HRS 75.8 78.4 0.247
There is no statistically significant difference in heart rate post operatively between
both groups.
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SYSTOLIC BP
POST OP - MEAN COMPARISON
SYSTOLIC BP DEXMEDITOMEDINE CLONIDINE P VALUE
0 HRS 112.6 123.3 0.001
0.5 HRS 114.6 122.3 0.001
1 HRS 116.5 123 0.001
1.5 HRS 115.6 120.3 0.043
2 HRS 115.5 122.4 0.001
2.5 HRS 113.8 123.8 0.001
3 HRS 117.1 125.5 0.001
3.5 HRS 113.2 123.8 0.001
4 HRS 111.1 119.8 0.001
4.5 HRS 111.6 121.4 0.001
5 HRS 110.3 122.8 0.001
5.5 HRS 110.5 124.6 0.001
6 HRS 111.8 126.2 0.001
10 HRS 113.7 125 0.001
14 HRS 118.4 123 0.012
18 HRS 115.2 118.3 0.17
22 HRS 112.3 125.5 0.001
24 HRS 116.8 123.8 0.001
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There is statistically significant difference in systolic BP post operatively between
both groups almost upto 24 hrs post-surgery.
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DIASTOLIC BP
POST OP - MEAN COMPARISON
DIASTOLIC BP DEXMEDITOMEDINE CLONIDINE P VALUE
0 HRS 67.8 81.6 0.001
0.5 HRS 69.9 80.7 0.001
1 HRS 69.8 78.9 0.001
1.5 HRS 69.7 76.5 0.001
2 HRS 73.2 78.1 0.001
2.5 HRS 74.5 78.9 0.007
3 HRS 78.1 78.9 0.477
3.5 HRS 73.3 79.8 0.001
4 HRS 73.5 81.5 0.001
4.5 HRS 74.8 79.06 0.008
5 HRS 75.3 80.2 0.002
5.5 HRS 71.4 77.9 0.003
6 HRS 73.5 77.5 0.041
10 HRS 76.4 77.3 0.637
14 HRS 78.3 78.4 0.963
18 HRS 75.3 80 0.001
22 HRS 78.1 80.4 0.083
24 HRS 79.6 80.6 0.421
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There is statistically significant difference in diastolic BP post operatively
between both groups almost up to 6 hours post-surgery. Where there is no significant
difference between groups post 6 hours
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MEAN ARTERIAL PRESSURE
POST OP - MEAN COMPARISON
MAP DEXMEDITOMEDINE CLONIDINE P VALUE
0 HRS 82.4 95.26 0.001
0.5 HRS 85.1 94.56 0.001
1 HRS 85.1 93.26 0.001
1.5 HRS 84.8 90.8 0.001
2 HRS 86.9 92.6 0.001
2.5 HRS 87.9 93.56 0.001
3 HRS 90.8 94.26 0.001
3.5 HRS 86 94.1 0.001
4 HRS 86.36 93.9 0.001
4.5 HRS 86.7 92.9 0.001
5 HRS 86.6 93.9 0.001
5.5 HRS 84.23 90.1 0.059
6 HRS 85.93 93 0.001
10 HRS 88.6 92.8 0.005
14 HRS 91.4 92.86 0.256
18 HRS 88.1 92.46 0.001
22 HRS 89.23 95.1 0.001
24 HRS 91.7 95.1 0.001
There is statistically significant difference in mean arterial pressure post
operatively between both groups almost upto 24 hrs post-surgery except during 14
hrs where the difference was much less.
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SPO2
POST OP - MEAN COMPARISON
SPO2 DEXMEDITOMEDINE CLONIDINE P VALUE
0 HRS 99 99 NIL
0.5 HRS 99 99 NIL
1 HRS 99 99 NIL
1.5 HRS 99 99 NIL
2 HRS 99 99 NIL
2.5 HRS 99 99 NIL
3 HRS 99 99 NIL
3.5 HRS 99 99 NIL
4 HRS 99 99 NIL
4.5 HRS 99 99 NIL
5 HRS 99 99 NIL
5.5 HRS 99 99 NIL
6 HRS 99 99 NIL
10 HRS 99 99 NIL
14 HRS 99 99 NIL
18 HRS 99 99 NIL
22 HRS 99 99 NIL
24 HRS 99 99 NIL
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There is no statistically significant difference in SpO2 post operatively
between both groups as it has been maintained same in both groups throughout post-
operative period at 99%.
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DURATION OF ANALGESIA
DURATION OF ANALGESIA
TYPE OF DRUG MEAN SD
DEXMEDITOMEDINE 11.25 2.16
CLONIDINE 7.68 1.30
P VALUE - 0.001
UNPAIRED T TEST
SIGNIFICANT
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25.73
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25
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26
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28
DEXMEDITOMEDINE CLONIDINE
MEAN DURATION OF ANALGESIA
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ADVERSE EFFECTS
NAUSEA NO OF PATIENTS PERCENTAGE
PRESENT 3 5%
ABSENT 57 95%
3
57
NAUSEA
PRESENT
ABSENT
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TYPE OF BLOCK
NAUSEA DEXMEDITOMEDINE CLONIDINE
PRESENT 0 3
ABSENT 30 27
P VALUE - 0.076
CHI SQUARE TEST
NON SIGNIFICANT
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D E XMED I TOMED INE C LON ID INE
NAUSEA
PRESENT ABSENT
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HEAD ACHE NO OF PATIENTS PERCENTAGE
PRESENT 3 5%
ABSENT 57 95%
3
57
HEAD ACHE
PRESENT
ABSENT
81
TYPE OF BLOCK
HEAD ACHE DEXMEDITOMEDINE CLONIDINE
PRESENT 0 3
ABSENT 30 27
P VALUE - 0.076
CHI SQUARE TEST
NON SIGNIFICANT
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BACK ACHE NO OF PATIENTS PERCENTAGE
PRESENT 3 5%
ABSENT 57 95%
5%
95%
BACK ACHE
PRESENT
ABSENT
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TYPE OF BLOCK
BACK ACHE DEXMEDITOMEDINE CLONIDINE
PRESENT 0 3
ABSENT 30 27
P VALUE - 0.076
CHI SQUARE TEST
NON SIGNIFICANT
0
30
3
27
0
5
10
15
20
25
30
35
PRESENT ABSENT
BACK ACHE
DEXMEDITOMEDINE CLONIDINE
84
BRADYCARDIA NO OF PATIENTS PERCENTAGE
PRESENT 6 10%
ABSENT 54 90%
10%
90%
BRADYCARDIA
PRESENT
ABSENT
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TYPE OF DRUG
BRADYCARDIA DEXMEDITOMEDINE CLONIDINE
PRESENT 2 4
ABSENT 30 27
P VALUE - 0.076
CHI SQUARE TEST
NON SIGNIFICANT
Nausea, Catheterisation, Headache, Back ache all are seen in only few cases
that too commonly in clonidine group.
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BROMAGE SCORE
BROMAGE SCORE – ROPIVACAINE WITH DEXMEDITOMEDINE
DURATION MEAN SD
POST OP 0 MIN 4 0
POST OP 15 MIN 3.37 0.62
POST OP 30 MIN 2.69 0.71
POST OP 1 HR 1.90 0.71
POST OP 2 HR 1 0
POST OP 4 HR 1 0
POST OP 8 HR 1 0
POST OP 12 HR 1 0
POST OP 24 HR 1 0
ANOVA
P VALUE - 0.001
SIGNIFICANT
4
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1 1 1 1 1
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POST OP 1
HR
POST OP 2
HR
POST OP 4
HR
POST OP 8
HR
POST OP
12 HR
POST OP
24 HR
MEAN BROMAGE SCORE -
DEXMEDITOMEDINE
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BROMAGE SCORE – ROPIVACAINE WITH CLONIDINE
DURATION MEAN SD
POST OP 0 MIN 3.83 0.47
POST OP 15 MIN 2.93 0.62
POST OP 30 MIN 2.16 0.62
POST OP 1 HR 1.13 0.33
POST OP 2 HR 1 0
POST OP 4 HR 1 0
POST OP 8 HR 1 0
POST OP 12 HR 1 0
POST OP 24 HR 1 0
ANOVA
P VALUE - 0.001
SIGNIFICANT
3.83
2.93
2.16
1.13 1 1 1 1 1
POST OP 0
MIN
POST OP
15 MIN
POST OP
30 MIN
POST OP 1
HR
POST OP 2
HR
POST OP 4
HR
POST OP 8
HR
POST OP
12 HR
POST OP
24 HR
MEAN BROMAGE SCORE - CLONIDINE
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MEAN BROMAGE SCORE - POST OP
DURATION RD RC P VALUE
POST OP 0 MIN 4 3.83 0.001
POST OP 15 MIN 3.52 2.93 0.001
POST OP 30 MIN 2.88 2.16 0.001
POST OP 1 HR 2.08 1.13 0.001
POST OP 2 HR 1 1 NIL
POST OP 4 HR 1 1 NIL
POST OP 8 HR 1 1 NIL
POST OP 12 HR 1 1 NIL
POST OP 24 HR 1 1 NIL
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
POST OP 0
MIN
POST OP
15 MIN
POST OP
30 MIN
POST OP 1
HR
POST OP 2
HR
POST OP 4
HR
POST OP 8
HR
POST OP
12 HR
POST OP
24 HR
BROMAGE SCORE
RD RC
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RAMSAY SEDATION SCORE
Time in
Minutes RD RC
P
VALUE
MEAN SD MEAN SD
0 3 0 3 0 1
60 3 0 3 0 1
120 3 0 2.76 0.43 0.007
180 3 0 2.76 0.43 0.007
240 2.84 0.37 2 0 0.001
480 2.84 0.37 2 0 0.001
720 2.56 0.5 2 0 0.001
0
0.5
1
1.5
2
2.5
3
3.5
0  HR 1  HR 2  HR 3  HR 4  HR 8  HR 12  HR
RAMSEY SEDATION SCORE
RD RC
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TOTAL DURATION OF SURGERY
TYPE OF DRUG MEAN SD
DEXMEDITOMEDINE 27.53 8.32
CLONIDINE 25.73 10.04
P VALUE - 0.453
UNPAIRED T TEST
SIGNIFICANT
Mean Duration of Motor block of RD Group is higher than RC group. Value 0.453
statistically significant
27.53
25.73
24.5
25
25.5
26
26.5
27
27.5
28
DEXMEDITOMEDINE CLONIDINE
MEAN DURATION OF SURGERY
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DISCUSSION
Postoperative analgesia offers not only relief of pain but also decreases
and mitigates the nociceptive impulses induced by trauma sometimes to blunt
autonomic reflexes. Untreated postoperative pains sometimes causes many
harmful acute and chronic effects. Neuroendocrine responses to pain end up in
raising sympathetic tone, augmented catecholamine release and catabolic
hormone secretions and also reduces the secretion of anabolic hormones.
The neuroendocrine stress response also augment other harmful
physiological effects like hypercoagulability, immunosuppressant, and deferral
in return of normal gastrointestinal function. Reduced postoperative respiratory
function is obvious especially after abdominal and upper thoracic surgeries.
Insufficient postoperative pain relief cause long term consequences like eating
disturbance, altered sleeping pattern and rise in pain perception during
subsequent painful experiences.
Benefits of regional anesthesia is not pain relief alone but also decrease
in need of general anesthetic, reduction in adverse events due to general
anesthetic agents, decreases neuro-hormonal stress responses, recover the
gastrointestinal functions, decreases intraoperative blood loss and expand the
defense mechanisms.
Enteral and parenteral analgesics used in postoperative analgesia, are
linked to unwanted events like gastrointestinal bleeding, nausea and vomiting,
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also sometimes causes sedation, acute exacerbation of asthma, respiratory
depression, thrombocytopenia and nephrotoxicity, hepatotoxicity, etc.
Many local anaesthetic agents like lidocaine, bupivacaine and
ropivacaine have been used for epidural block. Drugs like opioids, clonidine,
dexmedetomidine, midazolam and ketamine are used as adjuvant to local
anesthetics to increase the duration of analgesia, decrease the individual dose
of the drug and thereby decreasing the unwanted adverse effects.
Dexmedetomidine and Clonidine are good adjuvant to local anesthetic
agents when administered for epidural block. Addition of both has been found
to prolong the duration of analgesia without increasing adverse effects. When
administered epidurally, both drugs produce analgesia by interacting with
alpha 2 adrenergic receptors. These receptors are located on the superficial
laminae of spinal cord and brain stem nuclei associated with pain, so analgesia
can be produced at peripheral, spinal and brain stem sites.
Ideal anesthetic technique should be directed at three sites particularly
like periphery, sensory flow in nerves and cells in the central nervous system.
The various methods of providing pain relief have some adverse effects which
forbid their use, for eg, narcotics in children, because of their respiratory
depression.
Epidural anesthesia was chosen for our study because it is the simplest
and safest technique with a high success rate of single shot epidural injection
of local anaesthetic agents and adjuvants that prolong the postoperative
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analgesia. By this regional technique, troubles and complications of intubation
and polypharmacy due to general anesthesia are shunned.
In human beings, studies using epidural α-2 agonists like clonidine and
dexmedetomidine have been conducted previously which proved that it doesn’t
cause any neurological deficit. Hence to decrease neuraxial opioid induced side
effects such as respiratory depression, nausea, urinary retention and
pruritus.(32-34) α-2 agonists are being broadly assessed as substitute for post-
operative pain relief. Epidural administration of α-2 agonists is linked with
sedation, analgesia, anxiolysis, hypnosis and sympatholysis.(3-4) Clonidine
has been used successfully over the few years as adjuvants to anaesthetic for
above said purpose and the introduction of dexmedetomidine has further
broadened the scope of α-2 agonists in post-operative epidural analgesia.
Swifter onset of action of local anaesthetics, extended duration of post-
operative analgesia and stable hemodynamic parameters make these drugs
useful adjuvants in post-operative analgesia. (12, 19, 25)
In our study Patients of group I will receive 12ml of 0.75% ropivacaine
plus 2 mcg/kg of dexmeditomedine. Patients of group II will receive 12 ml of
0.75% ropivacaine plus 1.5mcg/kg of clonidine and its effectiveness as an
adjuvant in post-operative epidural analgesia was studied in 60 patients who
underwent surgery for inguinal hernia.
The demographic profile of our patients in both groups was comparable
with respect to age distribution.
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Hemodynamic stability:
The vital signs remained stable throughout the study period in both
groups which confirms the established effects of α-2 agonists in providing a
hemodynamically stable intra op and post-operative period. Although a slight
difference in heart rate and blood pressure (both systolic and diastolic) was
observed between both groups, dexmeditomedine had a better hemodynamic
stability and maintenance. when compared with clonidine. Both hypotension
and bradycardia were seen more in patients with clonidine as adjuvant. These
findings were similar with the study done by Sukhminder et al (42), in which
he compared the effectiveness dexmedetomidine and clonidine in epidural
anaesthesia but in pediatric population with upper abdominal surgeries when
bupivacaine was used.
Duration of analgesia:
The results of the our study have showed that addition of either
dexmedetomidine or clonidine as an adjuvant to epidural ropivacaine not only
increases the duration of analgesia but also provide a good sedation level in the
post-operative period. Dexmedetomidine has a significantly longer duration of
analgesic effect when compared to clonidine as it enables an earlier onset and
establishment of analgesia. These findings were similar to that of studies done
by Antonio et al (38) on epidural dexmedetomidine or clonidine in post
cholecystectomy analgesia and sedation.
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Another study done by El-Henaway et.al (12) on addition of clonidine
or dexmedetomidine to bupivacaine prolongs caudal analgesia in children.
They administered dexmedetomidine and clonidine, both in a dose of 2μg/kg
as an adjuvant with 0.25% bupivacaine caudally. They found that the duration
of analgesia was significantly higher in the group receiving bupivacaine-
dexmedetomidine mixture when compared to group receiving bupivacaine-
clonidine mixture. One another study done by Saadawy I (13), et.al compared
caudal bupivacaine 0.25% administered with dexmedetomidine 1μg/kg and
caudal bupivacaine alone. The duration of analgesia was significantly longer
with dexmedetomidine administration (p<0.001).
Neogi (39) et.al also did a comparative study between clonidine and
Dexmedetomidine where they were used as adjuvants to ropivacaine for caudal
analgesia in paediatric patients. They compared clonidine 1μg/kg and
dexmedetomidine 1μg/kg as adjuvants to ropivacaine 0.25% for caudal
analgesia. The mean duration of analgesia was 6.32±0.46 hours in ropivacaine,
13.17±0.68 hours in clonidine group and 15.26±0.86 hours in
dexmedetomidine group. This finding was similar to our study where duration
of analgesia was 11.25 hrs in dexmeditomedine group and 7.68 hrs in clonidine
group where the difference was also statistically significant.
Sedation score:
Next we evaluated the sedation of patients, in our study the results
indicates the sedation score between the two groups was similar in the first hour
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after study drug administration and they had profound sedation but arousable
by gentle tactile stimulation (i.e. Ramsay sedation score of 3). After two hours,
the percentage of dexmedetomidine group patients who have scored higher
sedation scores is in comparison with clonidine group. But the patients
remained awake but calm in both the groups (Score 2). Overall the sedation
scores were statistically significant statistically with administration of
dexmedetomidine. (11, 26, 27) This was correlated with the comparative study
done on Dexmedetomidine and clonidine in epidural anaesthesia,by
Sukhminder (42) et.al.They found that epidural dexmedetomidine produced
profound sedation in 36% of the patients who were arousable by gentle tactile
stimulation compared to achievement of similar sedation level in 16% of the
patients in clonidine group. Similarly 32 percent of the patients remained
awake but calm in clonidine group compared to 16% in dexmedetomidine
group who were equally cooperative and calm.
Coming to bromage score there is definite difference between groups
statistically at various levels. Though both drugs have a prolongation of motor
blockade, dexmeditomedine has a better effect in comparison to clonidine
which is similar to previous studies.
Side effects:
The side effect profile of both the drugs was quite favourable as none of
the patient in either group had profound deep sedation or respiratory depression
which correlates very well with other studies. We detected a little higher
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incidence of nausea, vomiting, head ache and bradycardia particularly in
clonidine group than dexmedetomidine group. This was not correlated with the
study done by Sukhminder (42), et.al where adverse effect profile was similar
in both groups.
We observed from our study that the total duration of surgery was not of
much difference between both groups which is similar to many studies done
before. Hence results of our observations show that in addition to prolonged
analgesia, dexmedetomidine has a favourable safety profile and stable
hemodynamics over clonidine, which correlates with the research done by
other reserachers.
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SUMMARY
This Double blinded prospective randomized controlled study was done
to evaluate the duration of analgesia as well as sedation and adverse effects of
dexmedetomidine vs. clonidine given via epidural route with ropivacaine in
patients who underwent surgery for inguinal hernia.
The following observations were made:
 The addition of dexmedetomidine to ropivacaine significantly
prolonged the duration of post operative analgesia.
 The addition of dexmedetomidine significantly prolonged the time
for further analgesic requirement. Most of the patients who received
dexmedetomidine may not require a 2nd rescue analgesia in post op
period for a longer periods.
 The addition of dexmedetomidine epidurally produced profound
sedation that compared to clonidine.
 The incidence of side effects such as hypotension, bradycardia and
vomiting are more in patients who received clonidine but difference
was not statistically significant between the groups.
 No episode of respiratory depression was noted in both the study
groups which are more common when opioids were used.
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CONCLUSION
To conclude that dexmedetomidine seems to be a better adjuvant to
epidural ropivacaine in maintaining analgesia. It has exceptional quality of
post-operative analgesia and a prolonged duration of arousable sedation with
little adverse effects. The hemodynamic parameters were well maintained with
dexmedetomidine. Overall the efficiency with dexmedetomidine was quite
satisfactory as compared to clonidine because of its superior sedative,
anxiolytic properties and analgesic properties.
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PROFORMA
COMPARATIVE STUDY OF EPIDURAL DEXMEDETOMIDINE AND
ROPIVACAINE WITH EPIDURAL CLONIDINE AND ROPIVACAINE FOR
INTRAOPERATIVE AND POSTOPERATIVE PAIN RELIEF IN INGUINAL
HERNIA SURGERIES
Name: Age: ASA PS:
Diagnosis: Height: Weight:
Group:
Drug used in Epidural:
Pre operative:
BP
PR
SPO2
Intra Operative
Immediately 3 min 6 min 9 min 12 min 15 min 30 min 45 min
BP
SBP
MBP
DBP
PR
SPO2
Heart rate
Onset of Sensory Block:
Highest Level of Sensory Block :
Time taken to Reach Highest Level of Sensory Block:
Two Segment Regression of Sensory Level:
Onset of Motor Block:
Duration of Motor Block:
Side Effects:
Duration of Analgesia :
POST OP
30 min 4 hours 8 hours 12 hours 16 hours 24 hours
BP
SBP
MBP
DBP
PR
SPO2
Heart rate
VAS
NehahspfSf;F mwptpg;G kw;Wk; xg;Gjy; gbtk; 
(kUj;Jt Ma;tpy; gq;Nfw;gj;w;F) 
Ma;T nra;ag;gLk; jiyg;G:  
gq;F ngWthpd; ngaH: 
gq;F ngWthpd; taJ: 
  gq;F ngWth; 
,jid  
Fwpf;fTk; 
1.  ehd; NkNy Fwpg;gpl;Ls;s kUj;Jt Ma;tpd; tptuq;fis gbj;J 
Ghpe;J nfhz;Nld;. vd;Dila re;Njfq;fis Nfl;fTk;> 
mjw;fhd jFe;j tpsf;fq;fis ngwTk; tha;g;gspf;fg;gl;Ls;sJ 
vd mwpe;J nfhz;Nld;. 
 
2.  ehd; ,t;tha;tpy; jd;dpr;irahf jhd; gq;Nfw;fpNwd;. ve;j 
fhuzj;jpdhNyh ve;j fl;lj;jpYk;> ve;j rl;l rpf;fYf;Fk; 
cl;glhky; ehd; ,t;tha;tpy; ,Ue;J tpyfp nfhs;syhk; vd;Wk; 
mwpe;J nfhz;Nld;. 
 
3.  ,e;j Ma;T rk;ge;jkhfNth> ,ij rhHe;J NkYk; Ma;T 
Nkw;fhs;Sk; NghJk; ,e;j Ma;tpy; gq;FngWk; kUj;JtH 
vd;Dila kUj;Jt mwpf;iffis ghHg;gjw;F vd; mDkjp 
Njitapy;iy vd mwpe;J nfhs;fpNwd;. ehd; Ma;tpy; ,Ue;J 
tpyfpf; nfhz;lhYk; ,J nghUe;Jk;; vd mwpfpNwd;. 
 
4.  ,e;j Ma;tpd; %yk; fpilf;Fk; jftiyNah> KbitNah 
gad;gLj;jpf; nfhs;s kWf;f khl;Nld;. 
 
5.  ,e;j Ma;tpy; gq;F nfhs;s xg;Gf; nfhs;fpNwd; vdf;F 
nfhLf;fg;gl;lmwpTiufspd; gb ele;J nfhs;tJld;> Ma;it 
Nkw;nfhs;Sk; kUj;Jt mzpf;F cz;ikAld; ,Ug;Ngd; vd;W 
cWjpaspf;fpNwd;. vd; cly; eyk; ghjpf;fg;gl;lhNyh> my;yJ 
vjpHghuhj> tof;fj;jpw;F khwhd Neha;Fwp njd;gl;lhNyh clNd 
,ij kUj;Jt mzpaplk; njhptpg;Ngd; vd cWjp mspf;Nwd;. 
 
 
gq;Nfw;gthpd; ifnahg;gk; / .................................................... ,lk; ........................................... 
fl;iltpuy; Nuif 
gq;Nfw;gthpd; ngaH kw;Wk; tpyhrk; ........................................................................................ 
Ma;thshpd; ifnahg;gk; /...................................................... ,lk; ............................................ 
Ma;thshpd; ngaH ......................................................................................................................... 
ikak; ...............................................................................................................................................  
fy;tpawpT ,y;yhjtw;F (ifNuif itj;jtHfSf;F) ,J mtrpak; Njit 
rhl;rpapd; ifnahg;gk; /...................................................... ,lk; ................................................ 
ngaH kw;Wk; tpyhrk; ................. ................................................................................................... 
 INFORMED CONSENT FORM 
 
Study Title   
 
Study Number   
 
Subject's Full Name   
 
Date of Birth/Age   
 
Address     
 
1.   I confirm that I have read and understood the information sheet dated for the above study 
and have had the opportunity to ask questions. 
OR I have been explained the nature of the study by the Investigator and had the 
opportunity to ask questions 
2.   I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason and without my medical care or legal 
rights being affected. 
3.   I understand that the sponsor of the clinical trial/project, others working on the 
Sponsor's behalf, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the trial. 
However, I understand that my Identity will not be revealed in any information released 
to third parties or published. 
4.   I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) 
5.   I agree to take part in the above study 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative:   
Signatory's Name   Date   
Signature of the Investigator   Date   
Study Investigator's Name   
Signature of the Witness   Date   
 
Name of the Witness
S.NO NAME TYPE TYPECODE AGE SEX DIAGNOSIS BASE HR BASE SBP BASE DBP
BASE
MAP
BASE
SPO2
IO HR 0
min
IO HR 5
min
IO HR 10
min
IO HR 15
min
1 ASIVATHAM RD 1 45 M RT INGUINAL HERNIA 68 108 70 82 98 74 72 68 72
2 VELSAMY RD 1 45 M RT INGUINAL HERNIA 74 126 92 103 99 84 74 74 68
3 DEVARAJ RD 1 60 M RT INGUINAL HERNIA 88 134 68 90 98 86 94 68 86
4 KALIAPERUMAL RD 1 52 M LT INGUINAL HERNIA 86 110 76 87 100 74 84 84 76
5 MUTHIAH RD 1 56 M RT INGUINAL HERNIA 96 128 94 105 100 98 86 76 86
6 PRABAKARAN RD 1 43 M RT INGUINAL HERNIA 86 104 82 89 99 64 72 62 82
7 MUTHU RD 1 55 M RT INGUINAL HERNIA 98 116 72 86 99 84 86 64 84
8 MURUGIAH RD 1 48 M RT INGUINAL HERNIA 94 128 68 93 99 82 70 68 66
9 SUDALAI RD 1 40 M LT INGUINAL HERNIA 86 136 72 93 99 68 84 62 84
10 SANTHANAM RD 1 60 M LT INGUINAL HERNIA 84 108 94 98 100 76 82 60 68
11 SUBRAMANIAN RD 1 57 M RT INGUINAL HERNIA 78 124 64 84 98 74 74 76 62
12 AANJA PERUMAL RD 1 58 M RT INGUINAL HERNIA 76 138 96 110 98 96 86 84 84
13 VEERA VAALUTHI RD 1 55 M LT INGUINAL HERNIA 82 106 78 87 99 74 90 82 76
14 MANIKKAM RD 1 47 M RT INGUINAL HERNIA 94 128 74 92 99 80 92 76 84
15 RAMA SUNDAR RD 1 40 M RT INGUINAL HERNIA 101 134 90 104 99 76 76 84 62
16 MURUGAN RD 1 44 M RT INGUINAL HERNIA 92 138 92 107 99 82 94 74 86
17 SIVANANTHAI RD 1 50 M LT INGUINAL HERNIA 84 108 86 93 98 76 82 68 82
18 SALIM RD 1 58 M RT INGUINAL HERNIA 94 116 64 81 98 74 76 68 76
19 RAMIAH RD 1 52 M RT INGUINAL HERNIA 84 124 84 97 100 86 90 74 82
20 PASUVAN RD 1 59 M LT INGUINAL HERNIA 82 138 96 110 99 90 68 60 64
21 GADWIN RD 1 40 M LT INGUINAL HERNIA 78 126 78 94 99 76 84 76 68
22 THANGARAJ RD 1 46 M LT INGUINAL HERNIA 68 126 86 99 99 86 62 68 64
23 LAKSHMANAN RD 1 55 M LT INGUINAL HERNIA 76 118 74 88 98 76 76 90 62
24 VICTOR RAJ RD 1 42 M LT INGUINAL HERNIA 92 126 98 107 98 74 80 76 68
25 NARAYANAN RD 1 60 M RT INGUINAL HERNIA 86 106 96 99 100 72 84 84 74
26 SHANMUGAVAEL RD 1 60 M RT INGUINAL HERNIA 72 128 82 97 100 68 86 64 68
27 AARUMUGASAMY RD 1 51 M RT INGUINAL HERNIA 64 114 78 90 99 68 90 84 62
28 GURUNATHAN RD 1 52 M RT INGUINAL HERNIA 82 126 68 87 98 74 76 68 74
29 KANNAN RD 1 42 M RT INGUINAL HERNIA 76 136 82 100 98 82 74 82 64
30 KARUPPASAMY RD 1 54 M RT INGUINAL HERNIA 74 142 78 99 98 68 64 68 62
S.NO NAME TYPE TYPECODE AGE SEX DIAGNOSIS BASE HR BASE SBP BASE DBP
BASE
MAP
BASE
SPO2
IO HR 0
min
IO HR 5
min
IO HR 10
min
IO HR 15
min
1 MARIAPPAN RC 2 46 M LT INGUINAL HERNIA 72 110 66 80 99 84 72 78 84
2 RAMAR RC 2 60 M RT INGUINAL HERNIA 84 136 88 104 99 80 76 87 82
3 SUBRAMANIAN RC 2 56 M RT INGUINAL HERNIA 94 124 68 86 99 96 76 68 94
4 CHINNATHAMBI RC 2 40 M LT INGUINAL HERNIA 76 100 74 82 99 86 82 94 76
5 GANAPATHI RC 2 58 M RT INGUINAL HERNIA 82 134 76 95 99 80 74 74 84
6 PRAMAN RC 2 44 M RT INGUINAL HERNIA 94 124 84 97 99 98 72 76 95
7 PERIYASAMY RC 2 60 M RT INGUINAL HERNIA 86 106 76 104 99 88 64 84 87
8 ARUNACHALAM RC 2 60 M LT INGUINAL HERNIA 82 130 92 104 99 88 68 75 68
9 MURUGAN RC 2 42 M RT INGUINAL HERNIA 76 122 76 91 98 82 74 72 84
10 SHAN MUGAM RC 2 45 M RT INGUINAL HERNIA 92 108 84 92 99 92 76 84 86
11 ARUMUGAM RC 2 55 M RT INGUINAL HERNIA 68 106 68 80 99 76 74 76 82
12 MUTHUSELVAN RC 2 42 M LT INGUINAL HERNIA 62 134 74 94 100 72 72 82 76
13 NATARAJAN RC 2 58 M RT INGUINAL HERNIA 76 142 86 104 100 84 86 68 94
14 SANKARAN RC 2 42 M RT INGUINAL HERNIA 92 106 74 84 100 98 84 74 82
15 SAMUEL PITCHAI RC 2 55 M RT INGUINAL HERNIA 84 132 84 100 100 86 76 94 80
16 SEKAR RC 2 58 M RT INGUINAL HERNIA 76 126 92 103 100 80 74 92 64
17 GANAPATHI RC 2 52 M RT INGUINAL HERNIA 96 134 68 90 99 100 74 86 76
18 KASIRAJA RC 2 42 M LT INGUINAL HERNIA 102 126 72 90 99 98 82 74 84
19 VELAYUTHAM RC 2 47 M LT INGUINAL HERNIA 80 124 74 90 99 86 76 76 68
20 MADASAMY RC 2 49 M RT INGUINAL HERNIA 72 126 84 98 99 82 84 74 96
21 ABDUL KATHAR RC 2 58 M LT INGUINAL HERNIA 86 124 86 98 99 84 84 78 76
22 PAUL RC 2 57 M LT INGUINAL HERNIA 94 106 72 83 99 86 86 84 84
23 KASIRAJA RC 2 44 M LT INGUINAL HERNIA 72 108 74 85 99 76 70 86 74
24 AUGUSTIN RC 2 47 M RT INGUINAL HERNIA 68 116 86 96 99 78 60 72 68
25 KRISHNARAJ RC 2 55 M RT INGUINAL HERNIA 96 126 84 98 99 102 82 86 72
26 MADASAMY RC 2 58 M LT INGUINAL HERNIA 78 104 76 85 100 86 86 84 94
27 MARIAPPAN RC 2 44 M RT INGUINAL HERNIA 92 136 84 101 100 98 76 94 68
28 SHAN MUGAM RC 2 45 M RT INGUINAL HERNIA 68 128 86 100 100 78 84 76 72
29 VINUHARAN RC 2 40 M LT INGUINAL HERNIA 64 132 76 94 100 76 68 84 68
30 SAKTHIRAJ RC 2 44 M RT INGUINAL HERNIA 74 116 74 88 100 78 82 74 94
IO HR 20
min
IO HR 25
min
IO HR 30
min
IO HR 45
min
IO HR 60
min
  IO HR 75
min
IO HR 90
min
IO SBP 0
min
IO SBP 5
min
IO SBP 10
min
IO SBP 15
min
IO SBP 20
min
IO SBP 25
min
IO SBP 30
MIN
IO SBP 45
MIN
IO SBP 60
MIN
IO SBP 75
MIN
80 68 74 60 74 76 86 110 100 112 114 112 110 112 114 120 122
74 74 76 76 64 84 94 132 122 128 126 122 118 120 118 122 124
68 84 84 74 82 82 92 140 128 134 130 128 124 122 124 118 120
64 76 72 90 70 62 76 118 100 116 118 120 118 120 126 120 118
68 82 60 76 76 72 94 134 120 130 128 124 120 122 124 126 120
70 68 84 84 64 68 76 110 98 112 114 116 122 118 126 120 128
62 64 78 70 82 6 82 124 114 120 122 124 126 124 128 130 122
74 82 82 64 86 74 94 134 118 130 128 130 128 124 130 134 132
68 64 64 68 62 68 76 140 136 134 132 128 124 118 126 130 128
64 64 66 72 70 72 92 110 102 108 106 104 106 110 116 120 118
84 68 82 80 76 64 76 126 110 120 118 120 124 120 124 128 116
82 64 72 76 68 60 94 140 122 138 132 128 126 122 126 130 128
80 68 76 84 72 78 72 110 94 112 110 112 116 120 124 128 126
68 60 68 70 74 64 76 130 102 126 126 124 120 118 118 120 124
60 72 64 64 68 72 68 140 120 134 132 128 126 120 126 124 128
64 76 62 76 62 68 90 142 122 136 130 132 128 124 130 128 132
72 64 74 80 84 74 74 146 96 110 112 110 112 110 118 120 122
90 84 64 74 72 76 84 124 102 120 118 120 118 116 122 124 126
82 60 62 86 64 82 62 132 106 126 124 124 124 128 120 126 128
68 82 80 64 76 68 82 140 124 136 134 130 128 134 136 134 132
74 64 76 82 90 62 64 132 108 124 120 118 122 132 116 122 124
84 76 74 84 76 70 76 134 106 120 116 120 118 122 124 126 122
76 72 68 74 90 68 92 120 112 120 118 116 120 126 124 126 118
82 64 72 62 74 62 84 130 116 124 120 118 122 128 130 134 128
68 62 64 74 98 76 76 110 100 110 118 122 128 130 132 124 126
64 76 68 68 76 68 74 130 114 130 126 128 130 136 128 130 132
82 82 62 64 94 76 68 122 110 120 124 122 134 132 130 136 134
60 64 64 84 86 74 82 130 120 130 128 126 132 136 132 138 136
72 84 62 84 84 70 76 142 122 134 134 130 126 126 128 126 126
86 68 82 74 68 74 74 144 132 140 142 140 136 134 130 132 128
IO HR 20
min
IO HR 25
min
IO HR 30
min
IO HR 45
min
IO HR 60
min
  IO HR 75
min
IO HR 90
min
IO SBP 0
min
IO SBP 5
min
IO SBP 10
min
IO SBP 15
min
IO SBP 20
min
IO SBP 25
min
IO SBP 30
MIN
IO SBP 45
MIN
IO SBP 60
MIN
IO SBP 75
MIN
84 92 72 68 78 84 76 132 102 106 104 104 106 108 110 120 118
68 87 68 74 84 68 78 140 108 112 108 104 104 104 110 120 116
72 67 64 94 86 62 76 138 100 116 120 118 116 118 120 126 124
94 86 84 76 68 64 74 124 96 102 104 106 106 110 112 122 122
76 80 86 82 84 84 94 142 106 110 108 110 112 110 114 122 124
84 68 92 74 86 86 86 138 110 114 116 110 110 108 110 124 120
92 76 76 68 84 72 82 128 96 102 104 104 108 110 106 118 128
76 64 70 68 76 86 72 142 100 104 110 106 108 108 110 116 120
74 76 78 74 64 70 76 134 96 100 106 106 110 112 114 118 118
72 74 68 76 74 94 84 120 94 102 106 104 102 104 110 118 120
84 82 94 68 86 76 72 124 92 104 100 102 100 102 104 120 122
82 68 84 68 82 84 64 140 106 108 108 110 112 108 110 124 122
76 72 68 74 68 74 92 148 108 106 110 106 108 110 112 126 124
92 84 68 86 74 76 84 126 96 100 102 104 102 104 106 114 118
86 86 82 62 72 74 74 146 116 120 122 120 126 124 126 124 120
84 72 72 82 80 72 82 134 132 130 132 134 130 128 130 126 120
72 68 90 68 68 84 64 142 110 116 114 112 114 112 114 114 116
76 64 76 64 72 60 86 130 102 110 108 110 110 108 110 122 118
84 76 82 86 62 76 76 132 104 106 108 112 100 102 104 110 110
76 84 86 84 68 74 68 134 106 110 106 108 106 110 114 120 122
84 68 87 82 76 84 74 136 108 116 120 118 120 122 124 128 122
72 84 92 68 64 74 68 124 96 102 108 106 110 108 110 122 124
90 68 76 72 74 86 76 114 96 104 106 108 110 108 112 118 122
74 62 84 74 62 76 84 126 94 100 104 110 108 110 112 122 122
75 78 72 64 76 82 76 128 100 106 110 108 112 110 108 118 122
68 72 68 68 82 80 84 134 106 112 114 106 110 108 110 116 118
74 68 62 90 84 76 62 146 104 110 118 120 116 116 118 120 122
92 62 76 62 70 84 76 134 108 114 116 122 116 120 122 120 122
74 74 74 82 64 70 84 142 112 118 122 124 120 118 122 128 130
90 68 76 74 72 64 74 126 96 102 108 106 110 112 110 112 114
IO SBP 90
MIN
IO DBP 0
min
IO DBP 5
min
IO DBP10
min
IO DBP
15 MIN
IO DBP
20 MIN
IO DBP
25 min
IO DBP
30 MIN
IO DBP
45 min
IO DBP
60 min
IO DBP
75 min
IO DBP
90 min
MAP 0
min
MAP 5
min
MAP 10
MIN
MAP 15
MIN
MAP 20
MIN
116 72 62 70 74 72 78 80 84 82 80 78 84 74 84 87 85
124 94 88 92 88 82 86 84 82 84 82 80 106 99 104 100 95
118 72 68 70 72 70 68 70 72 74 76 76 94 88 91 91 89
120 78 70 74 72 74 74 72 74 70 72 68 91 80 88 87 89
124 96 90 94 90 88 86 82 86 82 84 78 108 100 106 102 100
126 84 78 80 78 80 78 80 82 86 88 76 92 84 90 90 92
124 76 70 72 70 72 70 74 76 74 78 82 92 84 88 87 89
134 64 60 60 64 66 66 72 72 70 74 68 87 79 83 85 87
126 76 68 70 72 70 74 70 76 76 74 66 97 90 91 92 89
114 98 86 96 92 88 82 78 84 80 82 78 102 91 100 96 93
112 62 54 64 60 62 60 64 60 72 66 72 83 72 82 79 81
118 98 88 92 88 92 88 86 86 90 86 78 112 99 107 102 104
126 82 76 78 80 78 74 78 72 70 74 82 91 82 89 90 89
120 76 70 72 70 72 68 72 76 62 76 68 94 80 90 88 89
126 92 88 92 88 86 84 82 80 86 82 78 108 98 106 102 100
134 90 86 88 86 88 86 78 82 84 76 82 107 98 104 100 102
122 88 80 86 84 82 84 72 82 80 78 68 107 85 94 93 91
124 74 68 76 72 76 70 68 72 72 68 72 90 79 90 87 90
130 90 80 88 84 88 86 76 82 82 74 82 104 88 100 97 100
130 98 92 94 92 92 84 86 82 86 82 84 112 102 108 106 104
122 82 72 80 78 82 80 72 78 82 74 68 98 84 94 92 94
124 92 84 88 86 86 80 78 84 84 80 78 106 91 98 96 97
120 80 74 78 76 72 76 74 80 76 76 82 93 86 92 90 86
126 98 82 92 88 86 78 72 82 80 78 80 108 93 102 98 96
122 96 92 92 90 92 84 82 90 82 80 78 100 94 98 99 102
134 88 80 90 88 90 84 80 82 88 82 76 96 91 103 100 102
128 84 72 82 84 82 76 76 78 80 80 78 96 84 94 97 95
132 76 70 78 80 82 78 86 84 82 86 90 94 86 95 96 96
124 84 80 86 84 82 78 80 84 82 84 78 103 94 102 100 98
132 82 80 86 82 90 82 88 86 86 90 88 102 97 104 102 106
IO SBP 90
MIN
IO DBP 0
min
IO DBP 5
min
IO DBP10
min
IO DBP
15 MIN
IO DBP
20 MIN
IO DBP
25 min
IO DBP
30 MIN
IO DBP
45 min
IO DBP
60 min
IO DBP
75 min
IO DBP
90 min
MAP 0
min
MAP 5
min
MAP 10
MIN
MAP 15
MIN
MAP 20
MIN
122 84 62 66 66 66 66 70 72 78 80 82 100 75 79 78 78
118 88 60 64 64 64 66 70 72 76 76 80 105 76 80 78 77
122 82 62 68 72 70 72 72 74 80 82 80 100 74 84 88 86
124 80 62 68 72 70 70 74 72 76 80 82 94 73 79 82 82
120 88 70 72 70 68 70 76 74 78 82 82 106 82 84 82 82
124 84 72 74 74 68 66 70 74 76 82 78 102 84 87 88 82
126 80 60 64 66 62 64 66 68 76 82 78 96 72 76 78 76
124 88 56 62 66 62 64 70 72 72 76 78 106 70 76 80 76
120 82 52 58 60 62 64 70 72 80 82 80 99 66 72 75 76
122 78 54 58 60 64 66 70 68 72 68 78 92 67 72 75 77
124 82 56 60 62 64 62 68 70 76 76 80 96 68 74 74 76
124 88 66 70 68 72 68 70 72 72 74 76 105 79 82 81 84
120 86 70 72 72 70 72 74 72 76 78 80 106 82 83 84 82
118 82 66 72 72 68 70 72 70 74 76 82 96 76 81 82 80
124 84 62 68 72 72 70 74 76 76 80 82 104 80 85 88 88
124 78 72 74 70 72 72 76 80 76 82 78 96 92 92 80 92
118 86 62 68 70 72 68 70 74 78 82 80 104 78 84 84 85
120 82 64 68 72 70 68 72 74 82 82 82 98 76 82 84 83
112 80 60 66 74 68 64 74 76 80 78 80 97 74 79 85 82
120 82 64 70 68 72 70 76 80 82 80 82 99 78 83 80 84
120 86 62 68 72 72 70 78 82 78 82 84 102 77 84 88 87
122 78 62 68 74 68 70 72 76 80 82 84 93 73 79 85 8
124 72 58 64 66 62 64 76 74 82 80 82 86 70 77 79 77
126 80 62 68 72 74 70 78 80 76 78 80 95 72 78 82 86
124 78 60 70 70 74 72 82 80 82 80 82 94 73 82 83 85
120 82 62 68 72 70 70 78 84 78 82 84 99 76 82 86 82
120 86 62 64 68 72 70 76 82 78 82 80 106 76 79 84 88
120 84 60 66 64 70 72 76 80 82 80 82 100 76 82 81 87
132 88 72 78 82 80 82 80 82 84 80 82 106 85 91 95 94
116 82 60 68 74 76 74 76 78 88 84 80 96 72 79 85 86
MAP 25
MIN
MAP 30
MIN
MAP 40
MIN
MAP 60
MIN
MAP 75
MIN
MAP 90
MIN
SPO2 0
MIN
SPO2 5
MIN
SPO2 10
MIN
SPO2 15
MIN
SPO2 20
min
SPO2 25
MIN
SPO2 30
min
SPO2 45
min
SPO2 60
min
SP02 75
min
SPO2 90
min
88 90 94 94 94 90 99 99 99 99 99 99 99 99 99 99 99
96 96 94 96 96 94 99 99 99 99 99 99 99 99 99 99 99
86 87 89 88 90 90 99 99 99 99 99 99 99 99 98 99 99
88 88 91 86 87 85 99 99 99 99 99 99 99 99 98 99 99
97 95 98 96 101 93 99 99 99 99 99 99 99 98 98 98 99
92 92 96 97 101 92 99 99 99 98 99 99 99 98 98 98 99
88 90 93 92 92 96 99 99 99 98 98 99 99 98 98 98 99
96 89 91 91 93 90 99 99 99 98 98 98 99 98 99 98 99
90 86 92 94 92 86 99 99 99 99 98 98 99 99 99 98 99
90 88 94 93 94 90 99 98 99 99 99 98 99 99 99 98 99
81 82 81 90 82 85 99 99 99 99 99 98 99 99 99 99 99
100 98 99 103 100 91 99 99 99 99 99 99 99 99 99 99 99
88 92 89 89 91 96 100 99 99 100 100 100 99 99 99 99 99
85 87 90 81 92 85 100 100 99 100 100 100 99 99 99 99 99
98 94 95 98 97 94 99 99 98 99 99 99 99 99 99 99 99
100 93 98 98 94 99 99 99 98 99 99 99 98 99 99 99 99
93 84 94 93 92 86 99 99 98 99 99 99 98 99 99 99 99
86 84 88 89 87 89 99 99 99 99 99 99 98 98 98 99 99
98 93 94 96 92 99 99 99 99 99 99 99 98 98 98 99 99
98 102 100 102 98 99 99 100 100 100 99 99 99 98 98 99 99
94 92 90 95 90 86 99 99 99 99 99 99 99 98 99 99 99
92 92 97 92 94 93 99 99 99 99 99 99 99 99 99 99 99
90 91 94 92 90 94 99 99 99 99 99 99 99 99 99 98 99
92 90 98 98 94 95 99 99 99 99 99 99 99 99 99 98 99
98 98 104 96 95 92 99 99 99 99 99 99 99 99 99 98 99
99 98 97 102 98 95 99 99 99 99 99 99 99 99 99 99 99
95 94 95 98 98 94 99 99 99 99 99 99 99 99 99 99 99
96 102 100 100 102 104 99 98 98 99 99 99 99 99 99 99 99
94 95 98 96 98 93 99 98 99 99 99 99 99 99 99 99 99
100 103 100 101 102 102 99 99 99 99 99 99 99 99 99 99
MAP 25
MIN
MAP 30
MIN
MAP 40
MIN
MAP 60
MIN
MAP 75
MIN
MAP 90
MIN
SPO2 0
MIN
SPO2 5
MIN
SPO2 10
MIN
SPO2 15
MIN
SPO2 20
min
SPO2 25
MIN
SPO2 30
min
SPO2 45
min
SPO2 60
min
SP02 75
min
SPO2 90
min
79 82 84 92 92 95 99 99 99 99 99 99 99 99 99 99 99
78 81 84 90 89 92 99 99 99 99 99 99 99 99 99 99 99
86 87 89 95 96 94 99 99 99 99 99 99 99 99 99 99 99
82 87 85 91 94 96 99 99 99 99 99 99 99 99 99 99 99
84 87 87 92 96 94 98 99 99 99 99 99 99 99 99 99 99
80 82 80 92 94 93 98 99 99 99 99 99 99 99 99 99 99
78 80 80 90 97 94 98 99 99 99 99 99 99 99 99 99 99
78 82 84 86 90 93 98 99 99 99 99 99 99 99 99 99 99
79 81 86 92 94 93 99 99 99 99 99 99 99 99 99 99 99
78 81 82 87 85 92 99 99 99 99 99 99 99 99 99 99 99
74 79 81 90 91 94 99 99 99 99 99 99 99 99 99 99 99
82 82 84 89 90 92 99 99 99 99 99 99 99 99 99 99 99
84 86 85 92 93 93 100 99 99 99 99 99 99 99 99 99 99
80 82 82 87 90 94 100 99 99 99 99 99 99 99 99 99 99
88 90 92 92 93 96 100 99 99 99 99 99 99 99 99 99 99
91 93 96 92 94 93 100 99 99 99 99 99 99 99 99 99 99
83 84 87 90 93 92 99 99 99 99 99 99 99 99 99 99 99
82 84 86 95 94 94 99 99 99 99 99 99 99 99 99 99 99
76 83 85 90 88 90 99 99 99 99 99 99 99 99 99 99 99
82 87 91 94 94 94 99 99 99 99 99 99 99 99 99 99 99
86 92 96 94 95 96 99 99 99 99 99 99 99 99 99 99 99
83 84 87 94 96 96 99 99 99 99 99 99 99 99 99 99 99
79 86 86 94 94 95 99 99 99 99 99 99 99 99 99 99 99
82 88 90 91 92 95 99 99 99 99 99 99 99 99 99 99 99
85 91 89 94 94 96 99 99 99 99 99 99 99 99 99 99 99
83 88 92 90 94 96 99 99 99 99 99 99 99 99 99 99 99
85 89 94 92 95 93 99 99 99 99 99 99 99 99 99 99 99
86 90 94 94 94 94 99 99 99 99 99 99 99 99 99 99 99
94 92 95 98 96 98 99 99 99 99 99 99 99 99 99 99 99
86 88 88 96 94 92 99 99 99 99 99 99 99 99 99 99 99
VAS 0 hrs VAS 0.5hrs VAS 1 hrs
VAS 1.5
hrs VAS 2 hrs
VAS 2.5
hrs VAS 3 hrs
VAS 3.5
hrs VAS 4 hrs
VAS 4.5
hrs VAS 5 hrs
VAS 5.5
hrs VAS 6 hrs
VAS 10
hrs
VAS 14
hrs
VAS 18
hrs
VAS 22
hrs
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 0 0 0 2 2 2 2 3 3 2 2 2
0 0 0 0 0 0 0 0 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 1 1 1 1 3 3 3 3 3
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 0 0 0 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
0 0 0 0 0 1 1 1 2 2 2 2 3 3 2 2 2
VAS 0 hrs VAS 0.5hrs VAS 1 hrs
VAS 1.5
hrs VAS 2 hrs
VAS 2.5
hrs VAS 3 hrs
VAS 3.5
hrs VAS 4 hrs
VAS 4.5
hrs VAS 5 hrs
VAS 5.5
hrs VAS 6 hrs
VAS 10
hrs
VAS 14
hrs
VAS 18
hrs
VAS 22
hrs
0 0 0 0 1 1 1 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 1 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 1 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 3 3 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 3 3 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 3 3 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 3 3 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 3 3 3 3 3
0 0 0 0 0 1 2 3 3 3 3 3 3 3 3 3 3
0 0 0 0 0 1 2 3 3 3 3 3 3 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 2 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 2 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 2 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
0 0 0 0 1 1 2 3 3 3 3 3 2 2 3 3 3
VAS 24
hrs
DURATION OF POST
OPERATIVE ANALGESIA
(hrs)
PO HR 0
hrs
PO HR
0.5 hrs
PO HR 1
hrs
PO HR
1.5 hrs
PO HR 2
hrs
PO HR
2.5 hrs
PO HR 3
hrs
PO HR
3.5 hrs
PO HR 4
hrs
PO HR
4.5 hrs
PO HR 5
hrs
PO HR
5.5 hrs
PO HR 6
hrs
PO HR 10
hrs
2 10 87 82 68 87 68 74 84 68 84 74 96 84 74 96
2 11 68 94 72 67 64 94 86 62 84 78 76 84 78 76
2 9 94 76 94 86 84 76 68 64 86 84 84 86 84 84
2 8.5 74 84 76 80 86 82 84 84 70 86 74 70 86 74
2 7.5 76 95 84 68 92 74 86 86 60 72 68 60 72 68
2 15 84 87 92 76 76 68 84 72 82 86 72 82 86 72
2 12 75 68 76 64 70 68 76 86 86 84 94 86 84 94
2 11 72 84 74 76 78 74 64 70 76 94 68 76 94 68
2 10 84 86 72 74 68 76 74 94 84 76 72 84 76 72
4 9.5 76 82 84 82 94 68 86 76 68 84 68 68 84 68
2 8.5 82 76 82 68 84 68 82 84 82 74 94 82 74 94
2 13 68 94 76 72 68 74 68 74 86 74 86 76 72 68
2 12 74 82 92 84 68 86 74 76 98 82 74 84 76 64
2 9 94 80 86 86 82 62 72 84 74 96 76 84 86 84
2 11 92 64 84 72 72 82 80 84 78 76 84 68 87 82
2 14 84 92 72 68 78 84 76 86 84 84 72 84 92 68
2 13 68 87 68 74 84 68 78 70 86 74 90 68 76 72
2 12 72 67 64 94 86 62 76 60 72 68 74 62 84 74
2 11.5 94 86 84 76 68 64 74 82 86 72 75 78 72 64
2 13.5 76 80 86 82 84 84 94 86 84 94 68 72 68 68
2 12 84 68 92 74 86 86 86 76 94 68 74 68 62 90
2 15 92 76 76 68 84 72 82 84 76 72 92 62 76 62
2 12 76 64 70 68 76 86 72 68 84 68 74 74 74 82
2 13.5 74 76 78 74 64 70 76 82 74 94 90 68 76 74
2 12 72 74 68 76 74 94 84 84 72 72 82 80 72 82
2 9 84 82 94 68 86 76 72 72 68 90 68 68 84 64
2 9 82 68 84 68 82 84 64 76 64 76 64 72 60 86
2 15 76 72 68 74 68 74 92 88 70 68 94 76 72 68
2 11 92 84 68 86 74 76 84 82 76 74 82 92 84 68
2 8 86 86 82 62 72 74 74 86 88 94 80 86 86 82
VAS 24
hrs
DURATION OF POST
OPERATIVE ANALGESIA
(hrs)
PO HR 0
hrs
PO HR
0.5 hrs
PO HR 1
hrs
PO HR
1.5 hrs
PO HR 2
hrs
PO HR
2.5 hrs
PO HR 3
hrs
PO HR
3.5 hrs
PO HR 4
hrs
PO HR
4.5 hrs
PO HR 5
hrs
PO HR
5.5 hrs
PO HR 6
hrs
PO HR 10
hrs
3 8 76 80 86 82 84 84 76 72 68 74 86 68 94 76
3 7 84 68 92 74 86 86 92 84 68 86 64 70 68 80
3 9 92 76 76 68 84 72 86 86 82 62 76 78 74 68
3 8.5 76 64 70 68 76 86 84 72 72 82 74 68 76 76
3 7.5 74 76 78 74 64 70 72 68 90 68 82 94 68 64
3 11 72 74 68 76 74 94 76 64 76 64 68 84 68 76
3 9 84 82 94 68 86 76 84 76 82 86 72 68 74 74
3 9.5 82 68 84 68 82 84 76 84 86 84 84 68 86 82
3 6.5 76 72 68 74 68 74 84 68 87 82 86 82 62 68
4 5 92 84 68 86 74 76 72 84 92 68 72 72 82 72
4 5.9 86 86 82 62 72 74 90 68 76 72 68 90 68 84
3 8.5 84 72 72 82 80 72 74 62 84 74 64 76 64 86
3 7.5 72 68 90 68 68 84 75 78 72 64 75 78 72 64
3 8 76 64 76 64 72 60 68 72 68 68 68 72 68 68
3 7 84 76 82 86 62 76 74 68 62 90 74 68 62 90
3 8 76 84 86 84 68 74 92 62 76 62 92 62 76 62
3 8.5 84 68 87 82 76 84 74 74 74 82 74 74 74 82
3 9 72 84 92 68 64 74 90 68 76 74 90 68 76 74
3 7.5 62 72 74 76 72 68 74 76 80 86 82 84 72 84
3 6 82 80 72 92 84 68 86 84 68 92 74 86 86 75
3 8 68 68 84 86 86 82 62 92 76 76 68 84 72 68
3 7 64 72 60 84 72 72 82 76 64 70 68 76 86 74
3 5 86 62 76 72 68 90 68 74 76 78 74 64 70 92
3 8 84 68 74 76 64 76 64 72 74 68 76 74 94 74
3 6 82 76 84 84 76 82 86 84 82 94 68 86 76 90
3 7.5 68 64 74 76 84 86 84 82 68 84 68 82 84 74
3 8 72 74 86 84 68 87 82 76 72 68 74 68 74 72
3 7.5 74 62 76 72 84 92 68 92 84 68 86 74 76 86
3 8.5 64 76 82 90 68 76 72 86 86 82 62 72 74 84
3 8 68 82 80 74 62 84 74 84 72 72 82 80 72 76
PO HR 14
hrs
PO HR 18
hrs
PO HR 22
hrs
PO HR 24
hrs
PO SBP 0
hrs
PO SBP
0.5 hrs
PO SBP 1
hrs
PO SBP
1.5 hrs
PO SBP 2
hrs
PO SBP
2.5 hrs
PO SBP 3
hrs
PO SBP
3.5 hrs
PO SBP 4
hrs
PO SBP
4.5 hrs
PO SBP 5
hrs
PO SBP
5.5 hrs
PO SBP 6
hrs
76 84 86 84 120 122 120 126 124 126 124 110 116 114 112 114 112
84 68 87 82 130 132 134 130 128 130 126 102 110 108 110 110 108
72 84 92 68 116 114 112 114 112 114 114 110 106 108 134 130 128
90 68 76 72 110 108 110 110 108 110 122 116 120 118 112 114 112
74 62 84 74 106 108 112 100 102 104 110 102 108 106 110 110 108
75 78 72 64 110 106 108 106 110 114 120 104 106 108 112 100 102
68 72 68 68 116 120 118 120 122 124 128 100 104 110 108 106 110
74 68 62 90 102 108 106 110 108 110 122 106 110 108 118 120 122
92 62 76 62 104 106 108 110 108 112 118 112 114 106 106 110 108
74 74 74 82 100 104 110 108 110 112 122 120 104 106 108 110 108
90 68 76 74 106 110 108 112 110 108 118 118 100 104 110 108 110
90 68 68 84 112 114 106 110 108 110 116 120 106 110 108 112 110
76 64 72 60 110 118 120 116 116 118 120 122 112 114 106 110 108
68 72 74 92 114 116 122 116 120 122 120 122 110 118 120 116 116
76 70 76 84 118 122 124 120 118 122 128 124 114 116 122 116 120
64 68 74 74 102 108 106 110 112 110 112 118 118 122 124 120 118
74 84 72 82 120 122 120 126 124 126 124 120 102 108 106 110 124
62 86 84 64 130 132 134 130 128 120 122 120 126 124 110 106 128
76 68 60 86 116 114 112 114 112 130 132 134 130 128 116 120 112
82 84 76 76 110 108 110 110 108 116 114 112 114 112 102 108 108
84 86 74 68 106 108 112 100 102 110 108 110 110 108 104 106 102
70 84 84 74 110 112 126 124 120 106 108 112 100 102 100 104 110
64 76 74 68 104 106 114 118 118 110 106 108 106 110 106 110 122
72 64 86 76 124 126 124 120 124 116 120 118 120 122 112 114 108
76 74 76 84 128 130 126 120 124 102 108 106 110 108 104 104 108
68 86 82 76 112 114 114 116 118 104 106 108 110 108 110 106 108
68 82 80 84 108 110 122 118 120 100 104 110 108 110 106 106 110
74 68 76 62 102 104 110 110 112 106 110 108 112 110 106 104 102
86 74 84 76 110 114 120 122 120 112 114 106 110 108 100 102 100
62 72 70 84 122 124 128 122 120 110 118 120 116 116 108 110 112
PO HR 14
hrs
PO HR 18
hrs
PO HR 22
hrs
PO HR 24
hrs
PO SBP 0
hrs
PO SBP
0.5 hrs
PO SBP 1
hrs
PO SBP
1.5 hrs
PO SBP 2
hrs
PO SBP
2.5 hrs
PO SBP 3
hrs
PO SBP
3.5 hrs
PO SBP 4
hrs
PO SBP
4.5 hrs
PO SBP 5
hrs
PO SBP
5.5 hrs
PO SBP 6
hrs
72 68 78 74 128 124 120 122 124 126 120 126 110 120 118 130 128
86 82 84 84 114 116 122 118 126 120 128 140 122 138 132 118 120
92 74 86 86 122 124 126 124 128 130 122 110 94 112 110 128 124
76 68 84 72 128 130 128 124 130 134 132 130 128 124 122 114 116
70 68 76 86 132 128 124 118 126 130 128 118 120 118 120 122 124
78 74 64 70 106 104 106 110 116 120 118 128 124 120 122 128 130
68 76 74 94 118 120 124 120 124 128 116 114 116 122 118 132 128
94 68 86 76 132 128 126 122 126 130 128 122 124 126 124 106 104
84 68 82 84 110 112 116 120 124 128 126 128 130 128 124 128 130
68 74 68 74 126 124 120 118 118 120 124 132 128 124 118 130 134
68 86 74 76 132 128 126 120 126 124 128 106 104 106 110 126 130
82 62 72 74 130 132 128 124 130 128 132 134 106 120 116 116 120
72 82 80 72 112 110 112 110 118 120 122 120 112 120 118 124 128
90 68 68 84 118 120 118 116 122 124 126 130 116 124 120 126 130
76 64 72 60 124 124 124 128 120 126 128 110 112 116 120 124 128
82 86 62 76 134 130 128 134 136 134 132 126 124 120 118 118 120
86 84 68 74 120 118 122 132 116 122 124 132 128 126 120 126 124
87 82 76 84 116 120 118 122 124 126 122 130 132 128 124 130 128
92 68 64 74 118 116 120 126 124 126 118 112 110 112 110 118 120
78 72 76 82 120 118 122 128 130 134 128 118 120 118 116 122 124
72 68 82 76 118 122 128 130 132 124 126 124 124 124 128 120 126
68 62 68 94 126 128 130 136 128 130 132 134 130 128 134 136 134
62 76 74 82 124 122 134 132 130 136 134 120 118 122 132 116 122
74 74 94 80 128 126 132 136 132 138 130 128 124 122 122 124 126
68 76 92 64 120 128 126 116 120 118 118 120 118 120 126 124 126
76 82 86 76 130 122 124 102 108 106 128 124 120 122 128 130 134
82 76 74 84 134 132 134 104 106 108 114 116 122 118 130 132 124
68 94 76 68 130 128 126 100 104 110 122 124 126 124 136 128 130
74 82 74 96 120 118 114 106 110 108 128 130 128 124 132 130 136
94 80 78 76 128 116 112 112 114 106 132 128 124 118 136 132 138
PO SBP
10 hrs
PO SBP
14 hrs
PO SBP
18 hrs
PO SBP
22 hrs
PO SBP
24 hrs
PO DBP 0
hrs
PO
DBP0.5
hrs
PO DBP 1
hrs
PO DBP
1.5 hrs
PO DBP 2
hrs
PO DBP
2.5 hrs
PO DBP 3
hrs
PO DBP
3.5 hrs
PO DBP4
hrs
PO DBP
4.5 hrs
PO DBP 5
hrs
PO DBP
5.5 hrs
114 114 116 118 124 72 70 68 70 76 74 78 68 72 72 70 78
110 122 118 120 118 74 74 68 66 70 74 76 68 74 68 70 72
130 126 108 110 116 64 66 62 64 66 68 76 64 66 62 64 76
114 114 112 114 118 62 66 62 64 70 72 72 68 72 74 70 78
110 122 104 110 118 58 60 62 64 70 72 80 70 70 74 72 82
104 110 102 104 120 58 60 64 66 70 68 72 68 72 70 70 78
114 120 108 110 124 60 62 64 62 68 70 76 64 68 72 70 76
124 128 110 112 126 70 68 72 68 70 72 72 66 64 70 72 76
110 122 104 106 114 72 72 70 72 74 72 76 78 82 80 82 80
112 118 124 126 124 72 72 68 70 72 70 74 68 74 76 74 76
112 122 128 130 126 68 72 72 70 74 76 76 68 70 76 76 72
108 118 112 114 114 74 70 72 72 76 80 76 70 72 72 74 72
110 116 108 110 122 68 70 72 68 70 74 78 74 72 76 78 68
118 120 102 104 110 68 72 70 68 72 74 82 72 70 74 76 62
122 120 110 114 120 66 74 68 64 74 76 80 74 76 76 80 74
122 128 122 124 128 68 72 72 70 78 82 78 76 80 76 82 74
126 124 120 110 122 68 74 68 70 72 76 80 70 74 78 82 70
130 126 120 112 118 64 66 62 64 76 74 82 72 74 82 82 72
114 114 116 112 122 68 72 74 70 78 80 76 74 76 80 78 66
110 122 118 104 108 70 70 74 72 82 80 82 76 80 82 80 64
104 110 110 106 108 68 72 70 70 78 84 78 78 82 78 82 64
114 120 122 106 110 64 68 72 70 76 82 78 72 76 80 82 64
124 128 122 104 102 66 64 70 72 76 80 82 76 74 82 80 66
110 122 124 102 100 78 82 80 82 80 82 84 78 80 76 78 62
112 118 122 110 112 68 74 76 74 76 78 88 82 80 82 80 68
108 110 116 106 108 68 72 70 68 62 64 76 74 72 72 70 72
112 114 118 104 102 66 74 68 64 74 70 78 80 72 72 68 70
104 110 118 120 126 72 70 76 80 74 72 82 80 68 72 72 70
102 104 120 134 130 72 70 78 82 70 70 78 84 74 70 72 72
108 110 124 112 114 68 70 72 76 72 70 76 82 68 70 72 68
PO SBP
10 hrs
PO SBP
14 hrs
PO SBP
18 hrs
PO SBP
22 hrs
PO SBP
24 hrs
PO DBP 0
hrs
PO
DBP0.5
hrs
PO DBP 1
hrs
PO DBP
1.5 hrs
PO DBP 2
hrs
PO DBP
2.5 hrs
PO DBP 3
hrs
PO DBP
3.5 hrs
PO DBP4
hrs
PO DBP
4.5 hrs
PO DBP 5
hrs
PO DBP
5.5 hrs
124 122 110 120 118 70 72 70 68 70 72 76 82 82 74 82 72
118 120 122 138 132 74 72 74 74 72 74 86 82 86 82 84 72
120 122 94 112 110 94 90 88 86 82 86 72 78 82 74 68 90
122 118 102 126 126 80 78 80 78 80 82 78 84 84 80 78 78
126 124 120 134 132 72 70 72 70 74 76 74 80 76 76 82 70
128 124 122 136 130 75 64 66 66 72 72 72 82 80 78 80 64
124 118 126 110 112 70 72 70 74 70 76 82 90 82 80 78 72
106 110 102 120 118 96 92 88 82 78 84 80 82 88 82 76 92
122 132 106 126 124 64 60 62 60 64 60 76 78 80 80 78 60
132 140 124 136 134 92 88 92 88 86 86 86 84 82 86 90 88
128 132 108 124 120 78 80 78 74 78 72 80 84 82 84 78 80
118 134 106 120 116 72 70 72 68 72 76 88 86 86 90 86 70
116 120 112 120 118 92 88 86 84 82 80 94 90 88 86 92 74
128 130 116 124 120 88 86 88 86 78 82 80 78 80 78 88 94
126 124 130 134 132 86 84 82 84 72 82 72 70 72 70 86 80
124 118 126 130 128 70 72 68 72 76 62 76 68 66 66 72 72
128 110 116 120 118 88 86 84 82 80 86 82 78 70 74 88 60
132 120 124 128 116 86 88 86 78 82 84 76 82 88 82 78 70
122 122 126 130 128 84 82 84 72 82 80 78 68 62 60 64 96
126 120 124 128 126 72 76 70 68 72 72 68 72 92 88 86 64
128 118 118 120 124 84 88 86 76 82 82 74 82 78 74 78 92
132 120 126 124 128 92 92 84 86 82 86 82 84 72 68 72 78
124 124 130 128 132 78 82 80 72 78 82 74 68 86 84 82 72
122 110 118 120 122 86 86 80 78 84 84 80 78 88 86 78 92
118 116 122 124 126 76 72 76 74 80 76 76 82 82 84 72 88
128 128 120 126 128 88 86 78 72 82 80 78 80 88 86 78 72
126 134 136 134 132 90 92 84 82 90 82 80 78 86 76 82 82
132 132 116 122 124 88 90 84 80 82 88 82 76 88 86 84 82
134 122 124 126 122 84 82 76 76 78 80 80 78 82 76 76 78
136 126 124 126 118 80 82 78 86 84 82 86 90 86 82 90 82
PO DBP 6
hrs
PO DBP
10 hrs
PO DBP
14 hrs
PO DBP
18 hrs
PO DBP
22 hrs
PO DBP
24 hrs
PO MAP
0 hrs
PO MAP
0.5 hrs
PO MAP
1 hrs
PO MAP
1.5 hrs
PO MAP
2 hrs
PO MAP
2.5 hrs
PO MAP
3 hrs
PO MAP
3.5 hrs
PO MAP
4 hrs
PO MAP
4.5 hrs
PO MAP
5 hrs
82 78 82 80 76 78 88 87 85 88 92 91 93 82 86 86 84
76 80 82 80 82 80 92 93 90 87 89 92 92 79 86 81 83
74 82 80 84 78 82 81 82 78 80 81 83 88 79 79 77 87
80 76 78 82 78 82 78 80 78 79 82 84 88 84 88 88 84
80 82 80 80 82 80 74 76 78 79 80 82 90 80 82 84 84
84 78 82 82 84 80 75 75 78 79 83 83 88 80 83 82 84
82 78 82 78 88 84 78 81 82 81 86 88 93 76 80 84 82
80 82 80 72 78 80 80 81 83 82 82 84 88 76 79 82 87
82 84 80 72 76 76 82 83 82 84 85 85 90 86 92 88 90
78 88 84 74 80 82 81 82 82 82 84 84 90 85 84 86 85
70 76 80 72 76 80 80 84 84 84 86 86 90 84 80 85 87
70 78 82 74 78 82 86 84 83 84 86 90 89 86 93 84 85
70 72 76 74 76 82 82 86 88 84 85 88 92 90 85 88 87
64 76 74 68 76 82 83 86 87 84 88 90 94 88 93 88 90
70 78 80 72 72 76 83 90 86 82 88 91 96 90 88 89 94
72 82 80 72 80 82 79 84 83 83 89 91 89 90 92 91 96
70 78 84 68 72 68 85 90 85 88 89 92 94 86 83 88 90
70 76 82 70 76 76 86 88 86 86 93 89 95 88 91 96 91
70 74 76 72 72 74 84 86 86 84 89 96 94 94 94 96 90
66 68 76 72 76 78 83 82 86 84 90 92 92 88 91 92 87
70 72 72 70 74 76 80 82 84 80 86 92 88 88 91 88 89
70 72 80 76 76 80 79 82 90 88 90 90 88 85 84 87 88
70 68 72 80 76 82 78 96 84 87 90 90 90 86 84 91 88
68 70 76 74 78 82 93 96 94 94 94 93 96 91 93 91 89
70 72 72 74 82 82 88 92 92 89 92 86 94 90 90 90 88
74 72 76 76 80 78 82 86 84 84 80 77 86 85 84 84 83
72 70 74 80 82 80 80 86 86 82 89 80 86 90 84 84 80
74 76 76 82 78 82 82 81 87 90 86 93 91 89 82 82 83
76 80 76 76 80 82 84 84 92 95 86 84 90 91 86 85 81
70 74 78 74 82 80 86 88 90 91 88 93 90 94 84 85 84
PO DBP 6
hrs
PO DBP
10 hrs
PO DBP
14 hrs
PO DBP
18 hrs
PO DBP
22 hrs
PO DBP
24 hrs
PO MAP
0 hrs
PO MAP
0.5 hrs
PO MAP
1 hrs
PO MAP
1.5 hrs
PO MAP
2 hrs
PO MAP
2.5 hrs
PO MAP
3 hrs
PO MAP
3.5 hrs
PO MAP
4 hrs
PO MAP
4.5 hrs
PO MAP
5 hrs
70 68 76 82 82 74 89 89 86 86 88 90 90 96 91 89 94
74 74 86 82 86 82 87 86 90 88 90 89 100 101 98 100 100
88 86 72 78 82 74 103 101 100 98 97 100 88 88 86 86 82
80 78 78 84 84 80 96 95 96 93 96 99 96 99 98 94 92
72 70 74 80 76 76 92 89 89 86 91 94 92 92 90 90 94
66 66 72 82 80 78 85 77 79 80 86 88 87 97 94 92 91
70 74 82 90 82 80 86 88 88 89 88 93 93 98 93 94 91
88 82 80 82 88 82 108 104 100 95 94 99 96 95 100 96 92
62 60 76 78 80 80 79 77 80 80 84 82 92 94 96 96 93
92 88 86 84 82 86 103 100 101 98 96 97 98 100 97 98 99
78 74 80 84 82 84 96 96 94 89 94 89 96 91 89 91 88
72 68 88 86 86 90 91 90 90 86 91 93 102 102 92 100 96
72 74 74 72 74 84 98 95 94 92 94 93 103 100 96 97 100
90 88 86 82 86 80 98 97 98 96 92 96 95 95 92 93 98
78 80 78 80 82 82 98 97 96 98 88 96 90 83 85 85 97
70 72 70 74 76 90 91 91 88 92 96 86 94 87 85 84 87
64 66 66 72 72 82 98 96 96 98 92 98 96 96 89 91 98
72 70 74 70 76 78 96 98 96 92 96 98 91 98 102 97 93
92 88 82 78 84 84 95 93 96 90 96 95 91 82 78 77 79
60 62 60 64 60 84 88 99 87 88 91 92 88 87 101 98 96
88 92 88 86 86 86 95 99 100 94 98 96 91 96 93 90 94
80 78 74 78 72 90 103 104 99 102 97 100 98 100 91 88 92
70 72 68 72 76 78 93 95 98 92 95 100 94 85 96 96 98
88 86 84 82 80 70 100 99 97 97 100 102 96 94 100 98 92
86 88 86 78 82 64 90 90 92 88 93 90 94 94 94 96 90
82 80 78 80 82 72 102 98 93 82 90 88 94 94 98 98 94
74 82 86 90 88 82 104 105 100 89 95 90 91 90 98 90 98
80 86 82 78 82 78 102 102 98 86 89 95 95 92 100 98 101
80 80 78 82 76 82 96 94 88 86 88 89 96 95 97 92 94
88 86 86 90 88 86 96 93 89 94 94 90 101 102 98 94 105
PO MAP
5.5 hrs
PO MAP
6 hrs
PO MAP
10 hrs
PO MAP
14 hrs
PO MAP
18 hrs
PO MAP
22 hrs
PO MAP
24 hrs
PO SPO2
0 hrs
PO SPO2
0.5 hrs
PO SPO2
1 hrs
PO SPO2
1.5 hrs
PO SPO2
2 hrs
PO SPO2
2.5 hrs
PO SPO2
3 hrs
PO SPO2
3.5 hrs
90 92 90 92 92 90 93 99 99 99 99 99 99 99 99
84 86 90 95 92 94 92 99 99 99 99 99 99 99 99
94 92 98 95 92 88 93 99 99 99 99 99 99 99 99
90 90 88 90 92 90 94 99 99 99 99 99 99 99 99
91 89 91 94 88 91 92 99 99 99 99 99 99 99 99
85 90 86 91 88 90 93 99 99 99 99 99 99 99 99
86 91 90 94 88 95 97 99 99 99 99 99 99 99 99
90 94 96 96 84 89 95 99 99 99 99 99 99 99 99
90 90 92 94 82 86 88 99 99 99 99 99 99 99 99
87 88 96 95 90 95 96 99 99 99 99 99 99 99 99
84 83 88 94 90 94 95 99 99 99 99 99 99 99 99
85 83 88 94 86 90 92 99 99 99 99 99 99 99 99
82 82 84 89 85 87 95 99 99 99 99 99 99 99 99
80 81 90 89 76 85 91 99 99 99 99 99 99 99 99
88 86 92 93 84 86 90 99 99 99 99 99 99 99 99
89 87 95 96 88 94 97 99 99 99 99 99 99 99 99
83 88 94 97 85 84 86 99 99 99 99 99 99 99 99
83 89 94 96 86 88 90 99 99 99 99 99 99 99 99
84 84 87 88 86 85 90 99 99 99 99 99 99 99 99
78 80 82 91 87 85 88 99 99 99 99 99 99 99 99
78 80 82 84 83 84 86 99 99 99 99 99 99 99 99
77 83 86 93 91 86 90 99 99 99 99 99 99 99 99
80 87 86 90 94 85 88 99 99 99 99 99 99 99 99
79 81 83 91 90 86 88 99 99 99 99 99 99 99 99
80 82 85 87 89 91 92 99 99 99 99 99 99 99 99
83 85 84 87 89 88 88 99 99 99 99 99 99 99 99
82 84 84 87 92 89 87 99 99 99 99 99 99 99 99
81 83 85 87 94 92 96 99 99 99 99 99 99 99 99
82 84 87 85 90 98 98 99 99 99 99 99 99 99 99
82 84 85 88 90 92 91 99 99 99 99 99 99 99 99
PO MAP
5.5 hrs
PO MAP
6 hrs
PO MAP
10 hrs
PO MAP
14 hrs
PO MAP
18 hrs
PO MAP
22 hrs
PO MAP
24 hrs
PO SPO2
0 hrs
PO SPO2
0.5 hrs
PO SPO2
1 hrs
PO SPO2
1.5 hrs
PO SPO2
2 hrs
PO SPO2
2.5 hrs
PO SPO2
3 hrs
PO SPO2
3.5 hrs
91 89 86 91 91 94 88 99 99 99 99 99 99 99 99
87 89 88 97 95 103 98 99 99 99 99 99 99 99 99
102 100 97 88 83 92 86 99 99 99 99 99 99 99 99
90 92 92 91 90 98 95 99 99 99 99 99 99 99 99
87 89 88 90 93 95 94 99 99 99 99 99 99 99 99
85 87 86 89 95 98 95 99 99 99 99 99 99 99 99
92 89 90 94 102 91 90 99 99 99 99 99 99 99 99
96 93 90 90 88 98 94 99 99 99 99 99 99 99 99
82 84 80 94 87 95 94 99 99 99 99 99 99 99 99
102 106 102 104 97 100 102 99 99 99 99 99 99 99 99
95 95 92 97 92 96 96 99 99 99 99 99 99 99 99
85 88 84 103 92 97 98 99 99 99 99 99 99 99 99
90 90 88 89 85 89 95 99 99 99 99 99 99 99 99
104 103 101 100 93 98 93 99 99 99 99 99 99 99 99
94 94 95 93 96 99 98 99 99 99 99 99 99 99 99
87 86 89 86 91 94 102 99 99 99 99 99 99 99 99
82 84 86 80 86 88 90 99 99 99 99 99 99 99 99
90 90 90 89 88 93 90 99 99 99 99 99 99 99 99
13 101 99 95 94 99 98 99 99 99 99 99 99 99 99
83 81 83 80 84 82 98 99 99 99 99 99 99 99 99
101 100 104 98 96 97 98 99 99 99 99 99 99 99 99
97 87 96 89 94 89 102 99 99 99 99 99 99 99 99
86 87 89 86 91 93 96 99 99 99 99 99 99 99 99
102 100 98 92 94 93 97 99 99 99 99 99 99 99 99
100 99 98 96 92 96 94 99 99 99 99 99 99 99 99
91 99 96 94 93 96 90 99 99 99 99 99 99 99 99
98 90 96 102 105 103 98 99 99 99 99 99 99 99 99
97 96 101 98 90 95 93 99 99 99 99 99 99 99 99
95 98 98 92 96 92 95 99 99 99 99 99 99 99 99
98 104 102 99 101 100 96 99 99 99 99 99 99 99 99
PO SPO2
4 hrs
PO SPO2
4.5 hrs
PO SPO2
5 hrs
PO SPO2
5.5 hrs
PO SPO2
6 hrs
PO SPO2
10 hrs
PO SPO2
14 hrs
PO SPO2
18 hrs
PO SPO2
22 hrs
PO SPO2
24 hrs NAUSEA
HEAD
ACHE
BACK
ACHE
BRADYCA
RDIA
BRO
0MIN
BRO
15MIN
BRO
30MIN
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 4
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 3
99 99 99 99 99 99 99 99 99 99 0 0 0 1 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 4
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 1 4 3 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 2 1
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 2 1
99 99 99 99 99 99 99 99 99 99 0 0 0 0
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 2
PO SPO2
4 hrs
PO SPO2
4.5 hrs
PO SPO2
5 hrs
PO SPO2
5.5 hrs
PO SPO2
6 hrs
PO SPO2
10 hrs
PO SPO2
14 hrs
PO SPO2
18 hrs
PO SPO2
22 hrs
PO SPO2
24 hrs NAUSEA
HEAD
ACHE
BACK
ACHE
BRADYCA
RDIA
BRO
0MIN
BRO
15MIN
BRO
30MIN
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 1 1 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 2 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 2 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 3
99 99 99 99 99 99 99 99 99 99 1 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 1 1 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 2 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 1 1 3 3 2
99 99 99 99 99 99 99 99 99 99 0 1 0 0 4 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 2 1
99 99 99 99 99 99 99 99 99 99 1 0 0 0 4 3 2
99 99 99 99 99 99 99 99 99 99 0 1 0 0 3 3 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 4 3
99 99 99 99 99 99 99 99 99 99 1 1 0 0 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 2 1
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 2
99 99 99 99 99 99 99 99 99 99 0 0 0 0 4 3 3
99 99 99 99 99 99 99 99 99 99 0 0 0 1 3 2 1
99 99 99 99 99 99 99 99 99 99 0 0 0 0 3 3 2
BRO 1HR BRO 2HR BRO 4HR BRO 8HR BRO12HR
BRO
24HR RSS 0HR RSS 1HR RSS 2 HR RSS 3 HR RSS 4HR RSS 8 HR
RSS 12
HR
DURATION OF
SURGERY MIN
1 1 1 1 1 1 3 3 3 3 3 3 3 40
2 1 1 1 1 1 3 3 3 3 2 2 2 45
3 1 1 1 1 1 3 3 3 3 3 3 3 35
3 1 1 1 1 1 3 3 3 3 3 3 2 30
2 1 1 1 1 1 3 3 3 3 3 3 3 35
2 1 1 1 1 1 3 3 3 3 2 2 2 30
2 1 1 1 1 1 3 3 3 3 3 2 2 15
2 1 1 1 1 1 3 3 3 3 2 2 2 15
2 1 1 1 1 1 3 3 3 3 3 3 3 20
1 1 1 1 1 1 3 3 3 3 2 2 2 25
3 1 1 1 1 1 3 3 3 3 3 3 3 30
3 1 1 1 1 1 3 3 3 3 3 3 3 35
2 1 1 1 1 1 3 3 3 3 2 2 2 25
1 1 1 1 1 1 3 3 3 3 3 3 3 20
2 1 1 1 1 1 3 3 3 3 3 3 2 25
2 1 1 1 1 1 3 3 3 3 3 2 2 25
1 1 1 1 1 1 3 3 3 3 3 3 3 27
2 1 1 1 1 1 3 3 3 3 2 2 2 30
2 1 1 1 1 1 3 3 3 3 3 3 3 40
3 1 1 1 1 1 3 3 3 3 3 2 2 20
3 1 1 1 1 1 3 3 3 3 2 2 2 24
2 1 1 1 1 1 3 3 3 3 3 3 2 26
2 1 1 1 1 1 3 3 3 3 2 2 2 35
2 1 1 1 1 1 3 3 3 3 3 3 3 35
2 1 1 1 1 1 3 3 3 3 2 2 2 15
1 1 1 1 1 1 3 3 3 3 2 2 2 14
1 1 1 1 1 1 3 3 3 3 3 3 2 35
1 1 1 1 1 1 3 3 3 3 2 2 2 30
1 1 1 1 1 1 3 3 3 3 3 3 3 15
1 1 1 1 1 1 3 3 3 3 2 2 2 30
BRO 1HR BRO 2HR BRO 4HR BRO 8HR BRO12HR
BRO
24HR RSS 0HR RSS 1HR RSS 2 HR RSS 3 HR RSS 4HR RSS 8 HR
RSS 12
HR
DURATION OF
SURGERY MIN
1 1 1 1 1 1 3 3 3 3 3 2 2 35
1 1 1 1 1 1 3 3 2 2 2 2 2 40
1 1 1 1 1 1 3 3 3 3 3 2 2 15
1 1 1 1 1 1 3 3 2 2 2 2 2 25
1 1 1 1 1 1 3 3 2 3 2 2 2 20
2 1 1 1 1 1 3 3 2 2 2 2 2 25
1 1 1 1 1 1 3 3 3 2 2 2 2 20
1 1 1 1 1 1 3 3 2 2 2 2 2 12
1 1 1 1 1 1 3 3 3 2 2 2 2 27
1 1 1 1 1 1 3 3 2 2 2 2 2 25
1 1 1 1 1 1 3 3 3 3 3 2 2 40
2 1 1 1 1 1 3 3 3 2 2 2 2 10
1 1 1 1 1 1 3 3 2 2 2 2 2 20
1 1 1 1 1 1 3 3 3 3 3 2 2 25
1 1 1 1 1 1 3 3 3 3 2 2 2 25
1 1 1 1 1 1 3 3 3 2 2 2 2 45
1 1 1 1 1 1 3 3 3 3 3 2 2 30
1 1 1 1 1 1 3 3 2 2 2 2 2 30
1 1 1 1 1 1 3 3 3 3 2 2 2 10
2 1 1 1 1 1 3 3 3 2 2 2 2 14
2 1 1 1 1 1 3 3 2 2 2 2 2 30
1 1 1 1 1 1 3 3 3 3 2 2 2 35
1 1 1 1 1 1 3 3 2 2 2 2 2 13
1 1 1 1 1 1 3 3 3 3 2 2 2 25
1 1 1 1 1 1 3 3 2 2 2 2 2 30
1 1 1 1 1 1 3 3 2 2 2 2 2 25
1 1 1 1 1 1 3 3 3 3 2 2 2 16
1 1 1 1 1 1 3 3 2 2 2 2 2 40
1 1 1 1 1 1 3 3 3 3 3 2 2 45
1 1 1 1 1 1 3 3 2 2 2 2 2 20
